{"questions": [{"body": "What symptoms can be expected in women suffering from endometriosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37956828", "http://www.ncbi.nlm.nih.gov/pubmed/37944153", "http://www.ncbi.nlm.nih.gov/pubmed/35713579"], "ideal_answer": "Women suffering from endometriosis can experience a range of symptoms, including pelvic pain, dysmenorrhea (painful menstrual periods), heavy or irregular menstrual bleeding, pain during sexual intercourse, infertility, fatigue, and gastrointestinal symptoms such as bloating, constipation, or diarrhea. These symptoms can vary in severity and may be present throughout the menstrual cycle or worsen during menstruation. It is important to note that not all women with endometriosis will experience the same symptoms, and some may have no symptoms at all.", "exact_answer": [["Recurrent abdominal pain"], ["Cramping"], ["Dysmenorrhea (painful periods)"], ["Pelvic pain"], ["Pain during sexual intercourse"]], "type": "list", "id": "660bbc09fdcbea915f00002a", "snippets": [{"offsetInBeginSection": 1547, "offsetInEndSection": 1616, "text": "endometriosis, with and without chronic pain, anxiety, and depression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37956828", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Endometriosis is a chronic condition, with debilitating symptoms affecting all ages. Dysmenorrhea and pelvic pain ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37944153", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 497, "text": "recurrent abdominal pain, cramping and anxiety", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713579", "endSection": "abstract"}]}, {"body": "What is the epidemiology of breast cancer in men?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34458944", "http://www.ncbi.nlm.nih.gov/pubmed/31471487", "http://www.ncbi.nlm.nih.gov/pubmed/32952827"], "ideal_answer": "Breast cancer in men is rare, accounting for less than 1% of all breast cancer cases. However, the incidence of male breast cancer has been increasing worldwide. Risk factors for male breast cancer include increased longevity, obesity, testicular diseases and tumors, and germline mutations of BRCA2. Men generally present with breast cancer at an older age compared to women. Histologically, male breast cancer is often grade 2, hormone receptor positive, HER2 negative, and no special type carcinoma. Metastatic lesions to the male breast can occur and should be differentiated from primary carcinomas.", "type": "summary", "id": "660d6f0cfdcbea915f00003e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34458944", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 306, "text": "Risk factors include increased longevity, obesity, testicular diseases and tumours, and germline mutations of BRCA2. BRCA2 carriers have 80 times the risk of the general population", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34458944", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 384, "text": "Men generally present with breast cancer at an older age compared with women", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34458944", "endSection": "abstract"}, {"offsetInBeginSection": 418, "offsetInEndSection": 560, "text": "grade 2, hormone receptor positive, HER2 negative, and no special type carcinoma although in situ and invasive papillary carcinomas are common", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34458944", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 39, "text": "Breast cancer occurs in about 1% of men", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31471487", "endSection": "abstract"}, {"offsetInBeginSection": 780, "offsetInEndSection": 843, "text": "The most common histological type was invasive ductal carcinoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32952827", "endSection": "abstract"}]}, {"body": "What was tested in the PATCH-Trauma trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37314244", "http://www.ncbi.nlm.nih.gov/pubmed/33722875"], "ideal_answer": "The PATCH-Trauma trial tested the effectiveness of prehospital administration of tranexamic acid in patients with severe trauma at risk of acute traumatic coagulopathy.", "type": "summary", "id": "65cfd9071930410b13000024", "snippets": [{"offsetInBeginSection": 2067, "offsetInEndSection": 2542, "text": "ONCLUSIONS: Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8 hours did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo. (Funded by the Australian National Health and Medical Research Council and others; PATCH-Trauma ClinicalTrials.gov number, NCT02187120.).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37314244", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Protocol for a multicentre prehospital randomised controlled trial investigating tranexamic acid in severe trauma: the PATCH-Trauma trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33722875", "endSection": "title"}, {"offsetInBeginSection": 542, "offsetInEndSection": 833, "text": "METHODS AND ANALYSIS: The Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH-Trauma study) is comparing TXA, initiated prehospital and continued in hospital over 8\u2009hours, with placebo in patients with severe trauma at risk of acute traumatic coagulopathy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33722875", "endSection": "abstract"}]}, {"body": "Please list the psychoactive drugs used to treat mental health disorders.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37638529", "http://www.ncbi.nlm.nih.gov/pubmed/37348116", "http://www.ncbi.nlm.nih.gov/pubmed/35747039", "http://www.ncbi.nlm.nih.gov/pubmed/19004414"], "ideal_answer": "Psychoactive drugs used to treat mental health disorders include MDMA, ketamine, and psilocybin.", "exact_answer": [["MDMA"], ["Ketamine"], ["Psilocybin"]], "type": "list", "id": "65f48fa2c4010b4d7800000f", "snippets": [{"offsetInBeginSection": 169, "offsetInEndSection": 318, "text": ". Recently, the use of dissociative psychedelic substances such as ketamine and esketamine for depressive disorders has expanded treatment options. W", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37638529", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37638529", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37348116", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "There has been growth in the use of psychedelics by the global population in recent years. In addition to recreational and ritualistic use, recent research into psychedelics has brought advances for treating mental disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37348116", "endSection": "abstract"}, {"offsetInBeginSection": 507, "offsetInEndSection": 657, "text": "Psychoactive drugs such as MDMA, ketamine, and psilocybin have been shown to specifically target and decrease fear and anxiety pathways in the brain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747039", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004414", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "The purpose of this study was to investigate the safety of different doses of MDMA-assisted psychotherapy administered in a psychotherapeutic setting to women with chronic PTSD secondary to a sexual assault, a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004414", "endSection": "abstract"}]}, {"body": "Relevance of tumoral microbiome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37997816", "http://www.ncbi.nlm.nih.gov/pubmed/34506740"], "ideal_answer": "The tumoral microbiome, which refers to the microbial communities present within tumors, has been found to have a potential impact on cancer development, progression, and treatment response. Research suggests that the microbiome can influence various physiological processes and contribute to the initiation and progression of cancer. Understanding the role of the tumoral microbiome may lead to the development of novel therapeutic strategies for cancer treatment.", "type": "summary", "id": "660c0895fdcbea915f00002f", "snippets": [{"offsetInBeginSection": 737, "offsetInEndSection": 863, "text": "molecular pathogenic mechanisms shared throughout microbial niches that contribute to the initiation and progression of cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34506740", "endSection": "abstract"}, {"offsetInBeginSection": 944, "offsetInEndSection": 1022, "text": "how the microbiome may causally impact cancer and its treatment responsiveness", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34506740", "endSection": "abstract"}, {"offsetInBeginSection": 1028, "offsetInEndSection": 1161, "text": "how microorganisms or their secreted bioactive metabolites may be potentially harnessed and targeted as precision cancer therapeutics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34506740", "endSection": "abstract"}, {"offsetInBeginSection": 1600, "offsetInEndSection": 1727, "text": "Different pre\u2011clinical and clinical models are available for studying cancer development downstream of gut microbiome dysbiosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37997816", "endSection": "abstract"}, {"offsetInBeginSection": 1138, "offsetInEndSection": 1364, "text": "Dysbiosis of the gut microbiota can alter the metabolite profile, whilst increasing the levels of toxins, such as Bacteroides\u00a0fragilis toxin and colibactin and cytolethal distending toxin, which are responsible for oncogenesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37997816", "endSection": "abstract"}, {"offsetInBeginSection": 1412, "offsetInEndSection": 1519, "text": "impact of gut microbiome dysbiosis on the progression of different types of cancers associated with obesity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37997816", "endSection": "abstract"}, {"offsetInBeginSection": 787, "offsetInEndSection": 910, "text": "relationship between the gut microbiome and obesity\u2011associated malignancies, including colorectal, gastric and liver cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37997816", "endSection": "abstract"}, {"offsetInBeginSection": 1056, "offsetInEndSection": 1136, "text": "obesity\u2011associated microbiome alterations can lead to cancer and its progression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37997816", "endSection": "abstract"}]}, {"body": "Please list sources of orthobiologics", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36410877", "http://www.ncbi.nlm.nih.gov/pubmed/38090881", "http://www.ncbi.nlm.nih.gov/pubmed/36410882"], "ideal_answer": "Orthobiologics can be derived from various sources, including:\n1. Platelet-rich plasma (PRP): PRP is obtained from the patient's own blood, which is centrifuged to separate the platelet-rich plasma.\n2. Bone marrow aspirate: Bone marrow aspirate is collected from the patient's bone marrow, usually from the hip bone.\n3. Mesenchymal stem cells: These stem cells can be obtained from various sources, such as bone marrow, adipose tissue, or umbilical cord tissue.\n4. Adipose tissue: Adipose tissue can be harvested from the patient's own body, typically from areas with excess fat.\n5. Leukocyte-rich PRP: This type of PRP contains a higher concentration of white blood cells, which can be obtained from the patient's blood.\nIt is important to note that the use of these orthobiologics may vary depending on the specific condition being treated and the preferences of the healthcare provider.", "exact_answer": [["Platelet-rich plasma (PRP)"], ["Bone marrow aspirate"], ["Stem cells"], ["Blood"], ["Bone marrow"]], "type": "list", "id": "66088b42fdcbea915f000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Basic Science of Autologous Orthobiologics: Part 1. Platelet-Rich Plasma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36410877", "endSection": "title"}, {"offsetInBeginSection": 175, "offsetInEndSection": 441, "text": "These cellular therapies are often referred to as orthobiologics and are derived from patient's own tissues, such as blood, bone marrow, and adipose tissue to prepare platelet-rich plasma (PRP), bone marrow concentrate, and adipose tissue concentrate, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36410877", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "The use of orthobiologics such as platelet-rich plasma, bone marrow aspirate, and stem cells has been proposed as a biologic augmentation for treatment of various conditions of cartilage, tendon, and bone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090881", "endSection": "abstract"}, {"offsetInBeginSection": 66, "offsetInEndSection": 267, "text": "Orthobiologics continue to be studied for their ability to improve muscle healing. To date, the basic science research for treating muscle injuries with platelet-rich plasma or stem cell remains novel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36410882", "endSection": "abstract"}]}, {"body": "What are active ingredients of Xultophy pill?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36467033", "http://www.ncbi.nlm.nih.gov/pubmed/30740861", "http://www.ncbi.nlm.nih.gov/pubmed/28799414", "http://www.ncbi.nlm.nih.gov/pubmed/30335259"], "ideal_answer": "The active ingredients of Xultophy are insulin degludec and liraglutide.", "exact_answer": [["insulin degludec"], ["liraglutide"]], "type": "list", "id": "65d375011930410b1300004a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec and liraglutide for type 2 diabetes (T2D) patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36467033", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 421, "text": "AIM: To evaluate the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus comparator regimens for type 2 diabetes in Spain, based on real-world evidence.MATERIALS AND METHODS: Clinical data were taken from the European Xultophy Treatment Retrospective Audit (EXTRA) real-world evidence study in which patients failing to meet glycaemic targets were switched to IDegLira. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30740861", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28799414", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "[Basal insulin degludec - liraglutide fixed ratio combination (Xultophy\u00ae)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30335259", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Xultophy\u00ae (IDegLira) is a fixed ratio combination of basal insulin degludec and glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30335259", "endSection": "abstract"}]}, {"body": "Why does inflammatory bowel disease predispose to colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34757143"], "ideal_answer": "Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer (CRC) due to chronic inflammation. Chronic inflammation in IBD leads to neoplastic progression and the development of dysplastic precursor lesions in the colon. Colitis-associated CRC shares molecular similarities with sporadic CRC, and the microbiome and host immune system may play a role in its development.", "type": "summary", "id": "65f77ac9c4010b4d7800003c", "snippets": [{"offsetInBeginSection": 160, "offsetInEndSection": 350, "text": "Chronic inflammation is the driver of neoplastic progression, resulting in dysplastic precursor lesions that may arise in multiple areas of the colon through a process of field cancerization", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34757143", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 618, "text": "preclinical investigations have demonstrated a potential role for the microbiome in concert with the host immune system in the development of colitis-associated colorectal cancer (CAC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34757143", "endSection": "abstract"}]}, {"body": "What is the optimal antiemetic treatment for FOLFIRINOX chemotherapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37884842"], "ideal_answer": "Based on the given context, the optimal antiemetic treatment for FOLFIRINOX chemotherapy, a standard chemotherapy regimen for advanced pancreatic cancer, should include a combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA) for the prevention of chemotherapy-induced nausea and vomiting (CINV). However, it is important to note that CINV induced by FOLFIRINOX was poorly controlled even with this prophylactic antiemetic therapy, suggesting the need for enhanced antiemetic measures. Additionally, in patients with diabetes mellitus complications, sparing of steroids and glycemic control should be considered due to the risk of hyperglycemia.", "exact_answer": [["The optimal antiemetic treatment for FOLFIRINOX chemotherapy includes a combination of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA), dexamethasone (DEX), and neurokinin 1 receptor antagonists (NK1RA)."]], "type": "factoid", "id": "65f7798dc4010b4d78000038", "snippets": [{"offsetInBeginSection": 1255, "offsetInEndSection": 1408, "text": "CINV induced by mFFX was poorly controlled even with prophylactic antiemetic therapy using 5HT3RA, DEX, and NK1RA, and was found to persist beyond 5\u00a0days", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37884842", "endSection": "abstract"}]}, {"body": "Trends of acute epiglottitis in children.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33429180"], "ideal_answer": "The study analyzed trends in mortality due to acute epiglottitis in pediatric and adult populations before and after the adoption of Haemophilus influenza Type b vaccination (Hib). Pediatric and adolescent deaths accounted for 37.3% of the total deaths from acute epiglottitis. The mortality rate in children decreased significantly from 1979 to 2017, with an average annual percentage change (APC) of -11.1% from 1979 to 1990, 46.5% from 1990 to 1993, -61.6% from 1993 to 1996, and 1.1% from 1996 to 2017.", "type": "summary", "id": "660d17dffdcbea915f000037", "snippets": [{"offsetInBeginSection": 18, "offsetInEndSection": 174, "text": "trends in mortality due to acute epiglottitis before and after adoption of Haemophilus influenza Type b vaccination (Hib) in pediatric and adult populations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33429180", "endSection": "abstract"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1421, "text": "Mortality from acute epiglottitis decreased after widespread adoption of Hib vaccination in the US", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33429180", "endSection": "abstract"}, {"offsetInBeginSection": 1423, "offsetInEndSection": 1492, "text": "Adults are now more likely than children to die of acute epiglottitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33429180", "endSection": "abstract"}]}, {"body": "What is the first-line treatment for BRAF mutated advanced colorectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26338525", "http://www.ncbi.nlm.nih.gov/pubmed/33836264"], "ideal_answer": "The current standard first-line treatment for BRAF-mutated advanced colorectal cancer patients is chemotherapy with bevacizumab, as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status.", "exact_answer": [["The current standard therapies for first-line treatment of BRAF-mutated metastatic colorectal cancer (mCRC) are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status."]], "type": "factoid", "id": "66099a25fdcbea915f00001e", "snippets": [{"offsetInBeginSection": 883, "offsetInEndSection": 1132, "text": "The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33836264", "endSection": "abstract"}, {"offsetInBeginSection": 2733, "offsetInEndSection": 2947, "text": "FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338525", "endSection": "abstract"}, {"offsetInBeginSection": 2292, "offsetInEndSection": 2621, "text": "Median overall survival was 37\u00b71 months (95% CI 29\u00b77-42\u00b77) in the RAS and BRAF wild-type subgroup compared with 25\u00b76 months (22\u00b74-28\u00b76) in the RAS-mutation-positive subgroup (HR 1\u00b749, 95% CI 1\u00b711-1\u00b799) and 13\u00b74 months (8\u00b72-24\u00b71) in the BRAF-mutation-positive subgroup (HR 2\u00b779, 95% CI 1\u00b775-4\u00b746; likelihood-ratio test p<0\u00b70001). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338525", "endSection": "abstract"}]}, {"body": "What is the cause of Sydenham's chorea?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34353207", "http://www.ncbi.nlm.nih.gov/pubmed/31474378", "http://www.ncbi.nlm.nih.gov/pubmed/29287833", "http://www.ncbi.nlm.nih.gov/pubmed/30345135"], "ideal_answer": "Sydenham's chorea is caused by an immune-mediated response to a group A Beta-hemolytic streptococcal (GABHS) infection, specifically acute rheumatic fever (ARF).", "type": "summary", "id": "660c06b8fdcbea915f00002e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Sydenham's chorea is an autoimmune chorea emerging after a group A beta-hemolytic streptococcal (GABHS) infection, i.e. a rheumatic chorea with or without the presence of carditis or arthritis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34353207", "endSection": "abstract"}, {"offsetInBeginSection": 975, "offsetInEndSection": 1188, "text": "He was subsequently diagnosed with chorea by the neurology team. The cause of chorea was later determined to be SC, and the patient's throat swab came back positive for group A-beta hemolytic strep (GAS) infection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31474378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Sydenham's chorea (SC) is an immune-mediated hyperkinetic movement disorder, developing after group A Beta-hemolytic streptococcal (GABHS) infection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29287833", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Immune-mediated central nervous system manifestations of group A \u03b2-hemolytic Streptococcus (GABHS) infection include Sydenham's chorea", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30345135", "endSection": "abstract"}]}, {"body": "What is the function of the sodium leak channel (NALCN)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37569281", "http://www.ncbi.nlm.nih.gov/pubmed/37640554", "http://www.ncbi.nlm.nih.gov/pubmed/35911839", "http://www.ncbi.nlm.nih.gov/pubmed/35550517", "http://www.ncbi.nlm.nih.gov/pubmed/36175792"], "ideal_answer": "The sodium leak channel (NALCN) is responsible for mediating sodium leak currents and maintaining the resting membrane potential. It forms a complex with FAM155A, UNC79, and UNC80, and its activity depends on the presence of all these components. NALCN mutations can lead to neurodevelopmental diseases, and it has also been identified as a regulator of cancer metastasis and cell shedding from solid tissues.", "type": "summary", "id": "660710b7fdcbea915f000002", "snippets": [{"offsetInBeginSection": 213, "offsetInEndSection": 326, "text": "Sodium leak channel (NALCN) is widely expressed in the central nervous system and regulates neuronal excitability", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37569281", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "We tested the role of the sodium leak channel, NALCN, in pacemaking of dopaminergic neuron (DAN) subpopulations from adult male and female mice. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37640554", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 115, "text": " The NALCN encodes a sodium ion leak channel that regulates nerve-resting conductance and excitability. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35911839", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "NALCN channel mediates sodium leak currents and is important for maintaining proper resting membrane potential. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35550517", "endSection": "abstract"}, {"offsetInBeginSection": 18, "offsetInEndSection": 142, "text": "dium leak channel non-selective protein (NALCN) as a key regulator of cancer metastasis and nonmalignant cell dissemination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36175792", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 74, "text": "he NALCN channel regulates metastasis and nonmalignant cell dissemination", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36175792", "endSection": "title"}]}, {"body": "Which drugs were tested in the CodeBreaK 300 clinical trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37870968", "http://www.ncbi.nlm.nih.gov/pubmed/37921413"], "ideal_answer": "The drugs tested in the CodeBreaK 300 clinical trial were sotorasib, a KRAS G12C inhibitor, and panitumumab, an EGFR inhibitor.", "exact_answer": [["sotorasib"], ["panitumumab"], ["trifluridine-tipiracil"], ["regorafenib"]], "type": "list", "id": "65cf69541930410b13000006", "snippets": [{"offsetInBeginSection": 2215, "offsetInEndSection": 2665, "text": "CONCLUSIONS: In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment. Toxic effects were as expected for either agent alone and resulted in few discontinuations of treatment. (Funded by Amgen; CodeBreaK 300 ClinicalTrials.gov number, NCT05198934.).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37870968", "endSection": "abstract"}, {"offsetInBeginSection": 135, "offsetInEndSection": 316, "text": "Findings from the phase III CodeBreaK 300 trial indicate that adding the EGFR inhibitor panitumumab to sotorasib bests standard care for chemorefractory KRASG12C colorectal cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37921413", "endSection": "abstract"}]}, {"body": "Do elevated levels of procalcitonin help in diagnosing paediatric sepsis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31974673"], "ideal_answer": "Yes, elevated levels of procalcitonin (PCT) can help in diagnosing paediatric sepsis. In the study mentioned, PCT values were significantly higher in septic patients compared to non-septic patients, indicating its potential as a diagnostic biomarker. The area under the curve (AUC) for PCT was 0.748, suggesting good diagnostic accuracy. However, it is important to note that PCT is not the only diagnostic tool and should be used in conjunction with other clinical findings and biomarkers for a comprehensive evaluation of sepsis in paediatric patients.", "exact_answer": "yes", "type": "yesno", "id": "660c3591fdcbea915f000031", "snippets": [{"offsetInBeginSection": 1172, "offsetInEndSection": 1234, "text": "PCT appeared to be superior to MR-proADM in diagnosing sepsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31974673", "endSection": "abstract"}, {"offsetInBeginSection": 1492, "offsetInEndSection": 1593, "text": "CRP and PCT are already included in clinical practice to assess sepsis and estimate disease severity,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31974673", "endSection": "abstract"}, {"offsetInBeginSection": 1893, "offsetInEndSection": 1966, "text": "PCT appeared to be superior to MR-proADM in diagnosing paediatric sepsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31974673", "endSection": "abstract"}]}, {"body": "Is gout a very common inflammatory arthritis, which is caused by hyperbilirubinemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32541923", "http://www.ncbi.nlm.nih.gov/pubmed/34802900"], "ideal_answer": "Gout is a common inflammatory arthritis, but it is not caused by hyperbilirubinemia. Gout is primarily caused by hyperuricemia, which is the sustained elevation of serum urate levels resulting in the formation and deposition of monosodium urate crystals in and around the joints. Hyperbilirubinemia, on the other hand, refers to elevated levels of bilirubin in the blood and is not directly related to the development of gout.", "exact_answer": "no", "type": "yesno", "id": "660d6cc3fdcbea915f00003d", "snippets": [{"offsetInBeginSection": 495, "offsetInEndSection": 508, "text": "hyperuricemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34802900", "endSection": "abstract"}, {"offsetInBeginSection": 625, "offsetInEndSection": 701, "text": "effect of various dietary approaches on hyperuricemia among people with gout", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34802900", "endSection": "abstract"}, {"offsetInBeginSection": 746, "offsetInEndSection": 813, "text": "dietary factors appear to have a small effect on serum urate levels", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34802900", "endSection": "abstract"}, {"offsetInBeginSection": 1077, "offsetInEndSection": 1131, "text": "Urate-lowering therapy remains the mainstay of therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34802900", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "Gout is the most common inflammatory arthritis and occurs when hyperuricaemia, sustained elevation of serum urate levels resulting in supersaturation of body tissues with urate, leads to the formation and deposition of monosodium urate crystals in and around the joints", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32541923", "endSection": "abstract"}]}, {"body": "Does Lenvatinib plus pembrolizumab improve prognosis of advanced hepatocellular carcinoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/38039993"], "ideal_answer": "The addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma did not show a significant improvement in overall survival and progression-free survival compared to lenvatinib plus placebo. Therefore, the combination of lenvatinib plus pembrolizumab does not improve the prognosis of advanced hepatocellular carcinoma and does not support a change in clinical practice.", "exact_answer": "no", "type": "yesno", "id": "65d372231930410b13000047", "snippets": [{"offsetInBeginSection": 3603, "offsetInEndSection": 4010, "text": "INTERPRETATION: In earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039993", "endSection": "abstract"}]}, {"body": "What non-colonic tumors are associated with Lynch syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22933731"], "ideal_answer": "Non-colonic tumors associated with Lynch syndrome include tumors of the kidney, renal pelvis, ureter, bladder, small intestine, stomach, hepatobiliary tract, prostate, endometrium, breast, and ovary.", "exact_answer": [["kidney"], ["renal pelvis"], ["ureter"], ["bladder"], ["small intestine"]], "type": "list", "id": "6609997ffdcbea915f000019", "snippets": [{"offsetInBeginSection": 789, "offsetInEndSection": 1801, "text": "Following colorectal cancer, carriers of MMR gene mutations had the following 10-year risk of cancers in other organs: kidney, renal pelvis, ureter, and bladder (2%, 95% confidence interval [CI] = 1% to 3%); small intestine, stomach, and hepatobiliary tract (1%, 95% CI = 0.2% to 2%); prostate (3%, 95% CI = 1% to 5%); endometrium (12%, 95% CI = 8% to 17%); breast (2%, 95% CI = 1% to 4%); and ovary (1%, 95% CI = 0% to 2%). They were at elevated risk compared with the general population: cancers of the kidney, renal pelvis, and ureter (SIR = 12.54, 95% CI = 7.97 to 17.94), urinary bladder (SIR = 7.22, 95% CI = 4.08 to 10.99), small intestine (SIR = 72.68, 95% CI = 39.95 to 111.29), stomach (SIR = 5.65, 95% CI = 2.32 to 9.69), and hepatobiliary tract (SIR = 5.94, 95% CI = 1.81 to 10.94) for both sexes; cancer of the prostate (SIR = 2.05, 95% CI = 1.23 to 3.01), endometrium (SIR = 40.23, 95% CI = 27.91 to 56.06), breast (SIR = 1.76, 95% CI = 1.07 to 2.59), and ovary (SIR = 4.19, 95% CI = 1.28 to 7.97).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22933731", "endSection": "abstract"}]}, {"body": "Are FOLFIRINOX plus Bevacizumab the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33336844"], "ideal_answer": "No, FOLFIRINOX plus Bevacizumab is not the preferred therapy for left-sided RAS wild type advanced colorectal cancer with aggressive clinical presentation. The preferred upfront option for these patients is doublets plus anti-epidermal growth factor receptors (EGFRs). Initial therapy with FOLFOXIRI-bevacizumab has been shown to be superior to doublets plus bevacizumab, regardless of primary tumor sidedness and RAS/BRAF status. Although FOLFIRINOX plus Bevacizumab may be considered as a treatment option, it is not the preferred choice.", "exact_answer": "no", "type": "yesno", "id": "65f77701c4010b4d78000030", "snippets": [{"offsetInBeginSection": 500, "offsetInEndSection": 809, "text": "We selected patients with left-sided RAS and BRAF wild-type mCRC treated with first-line FOLFOX-panitumumab or FOLFOXIRI-bevacizumab in five randomized trials: Valentino, TRIBE, TRIBE2, STEAM, and CHARTA. A propensity score-based analysis was performed to compare FOLFOXIRI-bevacizumab with FOLFOX-panitumumab", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336844", "endSection": "abstract"}, {"offsetInBeginSection": 2089, "offsetInEndSection": 2232, "text": "No significant differences were observed, but FOLFOXIRI-bevacizumab achieved numerically superior survival outcomes versus FOLFOX-panitumumab. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336844", "endSection": "abstract"}, {"offsetInBeginSection": 2323, "offsetInEndSection": 2714, "text": "These observations suggest that although doublet chemotherapy plus anti-EGFRs remains the preferred treatment in patients with left-sided RAS/BRAF wild-type mCRC, FOLFOXIRI-bevacizumab is a valuable option able to provide similar, if not better, outcomes at the price of a moderate increase in toxicity and may be adopted based on patients' preference and potential impact on quality of life", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336844", "endSection": "abstract"}]}, {"body": "Can Connexin hemi channels be used for drug delivery?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30472182", "http://www.ncbi.nlm.nih.gov/pubmed/29861876"], "ideal_answer": "Yes, connexin hemichannels can be used for drug delivery. Connexin hemichannels are channels formed by connexin proteins that allow the passage of molecules up to 1,000 Da. These channels can be temporarily opened to create a pathway for drug delivery into cells. This approach has been explored in the context of photodynamic therapy (PDT), where certain channels, including connexin hemichannels, can be utilized to deliver photosensitizing compounds into cancer cells. By opening connexin hemichannels, hydrophilic substances such as photosensitizers can be delivered directly into the cytoplasm of cancer cells, enhancing the effectiveness of PDT. Additionally, connexin hemichannels can also be targeted for drug delivery in other therapeutic applications. However, further research is needed to optimize and develop clinically viable strategies for utilizing connexin hemichannels as drug delivery systems.", "exact_answer": "yes", "type": "yesno", "id": "660712a1fdcbea915f000003", "snippets": [{"offsetInBeginSection": 763, "offsetInEndSection": 920, "text": "he permeability of Cx43 channels to small molecules and macromolecules makes them highly attractive targets for delivering drugs directly into the cytoplasm.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30472182", "endSection": "abstract"}, {"offsetInBeginSection": 921, "offsetInEndSection": 1011, "text": "Cancer cells overexpressing Cx43 may be more permeable and sensitive to chemotherapeutics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30472182", "endSection": "abstract"}, {"offsetInBeginSection": 1213, "offsetInEndSection": 1434, "text": "n this context, certain channels lead to transitory plasma membrane permeability changes, such as pannexin, connexin hemmichannels, TRPV1-4 and P2\u00d77, which allow for the non-selective passage of molecules up to 1,000 Da. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29861876", "endSection": "abstract"}]}, {"body": "Should PDYD polymorphism determination be routinely performed in patients with colorectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35582139", "http://www.ncbi.nlm.nih.gov/pubmed/30348537"], "ideal_answer": "Yes, PDYD polymorphism determination should be routinely performed in patients with colorectal cancer. PDYD genetic variants are associated with severe toxicity in patients treated with fluoropyrimidines, which are commonly used in colorectal cancer treatment. Prospective genotyping for PDYD polymorphisms allows for dose individualization and reduces the risk of severe fluoropyrimidine-related toxicity. Implementing PDYD genotype-guided dosing as a standard of care can improve patient safety and treatment outcomes.", "exact_answer": "yes", "type": "yesno", "id": "65f77596c4010b4d7800002c", "snippets": [{"offsetInBeginSection": 569, "offsetInEndSection": 759, "text": "Host genetic variants in the rate limiting enzyme dihydropyrimidine dehydrogenase (DPYD) gene are related to the occurrence of extremely severe, early onset toxicity in FP treated patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582139", "endSection": "abstract"}, {"offsetInBeginSection": 3168, "offsetInEndSection": 3333, "text": "Prospective DPYD genotyping was feasible in routine clinical practice, and DPYD genotype-based dose reductions improved patient safety of fluoropyrimidine treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30348537", "endSection": "abstract"}]}, {"body": "What is the estimated impact of social determinants of health on health outcomes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37501568", "http://www.ncbi.nlm.nih.gov/pubmed/33614572", "http://www.ncbi.nlm.nih.gov/pubmed/37131177"], "ideal_answer": "The estimated impact of social determinants of health on health outcomes is significant. Studies have shown that social determinants, such as socioeconomic status, education level, and access to healthcare, directly and indirectly influence health outcomes. These determinants contribute to health disparities and can affect life expectancy, self-perceived health, and disease management. Addressing social determinants of health is crucial in reducing health inequities and improving overall health outcomes.", "exact_answer": [["The study found that social determinants of health have a significant impact on health outcomes."], ["For life expectancy, social determinants contribute directly and indirectly through lifestyle factors."], ["For self-perceived health, both social and lifestyle determinants have a direct impact."], ["Addressing lifestyle factors within the context of broader social determinants is important for improving health outcomes."], ["Redistributive measures aimed at reducing social gradients in health are effective health promotion policies."]], "type": "factoid", "id": "65f86b3ac4010b4d78000058", "snippets": [{"offsetInBeginSection": 658, "offsetInEndSection": 751, "text": "social determinants contribute directly and indirectly (through lifestyle) to life expectancy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37501568", "endSection": "abstract"}, {"offsetInBeginSection": 2230, "offsetInEndSection": 2302, "text": "community SDOH play an important role in diabetes control and management", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33614572", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 406, "text": "adolescent childbearing in ten countries according to social determinants like milieu (rural-urban), education level, wealth quintiles, territoriality (countries, regions) and nationality", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37131177", "endSection": "abstract"}, {"offsetInBeginSection": 1194, "offsetInEndSection": 1335, "text": "Poor, rural and non-educated adolescent girls are more exposed to teenage childbearing than their counterparts-rich, urban and educated girls", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37131177", "endSection": "abstract"}, {"offsetInBeginSection": 1348, "offsetInEndSection": 1468, "text": "According to different social determinants, sensible variations are seen in terms of adolescent pregnancy and motherhood", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37131177", "endSection": "abstract"}, {"offsetInBeginSection": 1565, "offsetInEndSection": 1760, "text": "reduce child marriage and pregnancy by acting on social determinants of health, targeting disadvantaged girls coming mainly from marginalised groups and poor families living in remote rural zones", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37131177", "endSection": "abstract"}]}, {"body": "Please list the symptoms of Havana syndrome", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35962646", "http://www.ncbi.nlm.nih.gov/pubmed/34873135", "http://www.ncbi.nlm.nih.gov/pubmed/37965360", "http://www.ncbi.nlm.nih.gov/pubmed/35505689"], "ideal_answer": "The symptoms of Havana syndrome include tinnitus, visual problems, vertigo, cognitive difficulties, vestibular symptoms, neurobehavioral symptoms, auditory-vestibular symptoms, neuropsychological symptoms, mild traumatic brain injury-like symptoms, elevated IL-1B, IL-10, NGF, and norepinephrine levels, depressed BDNF, GDNF, IGF1, and glutamate expression, elevated CRH and IL-6 levels, and prolonged illness with cognitive impairment.", "exact_answer": [["tinnitus"], ["visual problems"], ["vertigo"], ["cognitive difficulties"], ["auditory-vestibular symptoms"]], "type": "list", "id": "65f857b0c4010b4d7800004f", "snippets": [{"offsetInBeginSection": 132, "offsetInEndSection": 345, "text": "have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties, after they encountered strange sounds; this has been called \"Havana syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35962646", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Clinical and Psychological Factors Associated With Return to Work Among United States Diplomats Who Sustained a Work-Related Injury While on Assignment in Havana, Cuba.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34873135", "endSection": "title"}, {"offsetInBeginSection": 1, "offsetInEndSection": 205, "text": "ntroduction: In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Diplomats representing the USA have reported with unusual neurologic symptoms and MRI changes after being posted in Havana, Cuba between late 2016 and 2018", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35505689", "endSection": "abstract"}]}, {"body": "What part of the cell is mitophagy associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37488884", "http://www.ncbi.nlm.nih.gov/pubmed/37549565", "http://www.ncbi.nlm.nih.gov/pubmed/37862201"], "ideal_answer": "Mitophagy is associated with the mitochondria, which are critical cellular energy resources and central to the life of the neuron. Mitophagy selectively clears damaged or dysfunctional mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis.", "exact_answer": [["Mitophagy is associated with the mitochondria."]], "type": "factoid", "id": "660877c8fdcbea915f000008", "snippets": [{"offsetInBeginSection": 360, "offsetInEndSection": 510, "text": "Mitophagy, or selective autophagy of mitochondria, is an essential pathway to preserve mitochondrial homeostasis by clearing up damaged mitochondria. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37488884", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Mitophagy is an essential physiological process that eliminates damaged mitochondria via lysosomes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37549565", "endSection": "abstract"}, {"offsetInBeginSection": 95, "offsetInEndSection": 250, "text": "Mitophagy selectively clears damaged or dysfunctional mitochondria through autophagic machinery to maintain mitochondrial quality control and homeostasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37862201", "endSection": "abstract"}]}, {"body": "New treatments in multiple sclerosis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33620411", "http://www.ncbi.nlm.nih.gov/pubmed/35674067"], "ideal_answer": "Recent advancements in the treatment of multiple sclerosis (MS) include the use of high efficacy disease modifying therapies in the early, inflammatory phase of the disease. Bruton's tyrosine kinase inhibitors have emerged as important therapeutic targets for both relapsing and progressive forms of MS. Additionally, there are ongoing clinical trials investigating therapies targeting remyelination, chronic Epstein-Barr virus infection, and dysbiosis of the gut microbiome. These advancements offer hope for the development of better and more effective treatments for MS.", "exact_answer": [["High efficacy disease modifying therapies"], ["Bruton's tyrosine kinase inhibitors"], ["Therapies targeting remyelination"], ["Strategies targeting chronic Epstein-Barr virus infection"], ["Strategies targeting dysbiosis of the gut microbiome"]], "type": "list", "id": "660d7491fdcbea915f000041", "snippets": [{"offsetInBeginSection": 1687, "offsetInEndSection": 1872, "text": "interferons, glatiramer acetate, teriflunomide, sphingosine 1-phosphate receptor modulators, fumarates, cladribine, and 3 types of monoclonal antibodies. One additional DMT, ocrelizumab", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33620411", "endSection": "abstract"}]}, {"body": "Should UGT1A1 alteration be routinely determined in colorectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28637434"], "ideal_answer": "Based on the findings of this study, UGT1A1 alteration should be routinely determined in colorectal cancer patients receiving irinotecan-based chemotherapy. The UGT1A1*6 and UGT1A1*28 variants were found to be associated with severe neutropenia, while UGT1A1*27 was associated with worse overall survival. Determining UGT1A1 alterations can help identify patients at higher risk of toxicity and guide treatment decisions to optimize patient outcomes.", "exact_answer": "yes", "type": "yesno", "id": "65f775e8c4010b4d7800002d", "snippets": [{"offsetInBeginSection": 1879, "offsetInEndSection": 2039, "text": "An examination of more UGT1A loci, except for UGT1A1*6 and UGT1A1*28, was not helpful to improve the predictive value of irinotecan-based toxicity and efficacy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637434", "endSection": "abstract"}]}, {"body": "What is the cause of Brazilian spotted fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32267390", "http://www.ncbi.nlm.nih.gov/pubmed/31504641"], "ideal_answer": "The causative agent of Brazilian spotted fever is Rickettsia rickettsii, a bacterium transmitted mainly by the tick Amblyomma sculptum. Capybaras serve as major hosts for the tick, and humans can become infected through tick bites.", "exact_answer": [["The causative agent of Brazilian spotted fever is Rickettsia rickettsii."]], "type": "factoid", "id": "660c0486fdcbea915f00002d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "The bacterium Rickettsia rickettsii is the agent of Brazilian spotted fever (BSF)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504641", "endSection": "abstract"}, {"offsetInBeginSection": 810, "offsetInEndSection": 823, "text": "R. rickettsii", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504641", "endSection": "abstract"}, {"offsetInBeginSection": 647, "offsetInEndSection": 660, "text": "R. rickettsii", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504641", "endSection": "abstract"}, {"offsetInBeginSection": 1426, "offsetInEndSection": 1501, "text": "A. sculptum ticks were infected by R. rickettsii in other BSF-endemic areas", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504641", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Rickettsia rickettsii is the causative agent of Brazilian spotted fever", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32267390", "endSection": "abstract"}]}, {"body": "In what part of the body would a periprosthetic infection occur?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37380142", "http://www.ncbi.nlm.nih.gov/pubmed/37393964", "http://www.ncbi.nlm.nih.gov/pubmed/38046455"], "ideal_answer": "A periprosthetic infection can occur in the area surrounding a prosthetic joint, such as the hip or knee.", "exact_answer": [["A periprosthetic infection can occur in the area surrounding an implanted joint prosthesis."]], "type": "factoid", "id": "66088ffafdcbea915f00000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 327, "text": "BACKGROUND: The aim of the present study was to compare causative bacteria and their antibiotic resistance profiles in patients developing a periprosthetic joint infection (PJI) based on preoperative prophylactic antibiotic regimens in primary total hip (THA) and primary total and unicompartmental knee arthroplasty (TKA/UKA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37380142", "endSection": "abstract"}]}, {"body": "What receptors are targeted by Retatrutide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37366315", "http://www.ncbi.nlm.nih.gov/pubmed/37086147", "http://www.ncbi.nlm.nih.gov/pubmed/37385280"], "ideal_answer": "Retatrutide targets the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon receptors.", "exact_answer": [["glucose-dependent insulinotropic polypeptide receptor"], ["glucagon-like peptide 1 receptor"], ["glucagon receptor"]], "type": "list", "id": "65cfce461930410b1300001a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37366315", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37086147", "endSection": "title"}, {"offsetInBeginSection": 282, "offsetInEndSection": 581, "text": "AREAS COVERED: A multiple-ascending dose phase 1b clinical trial of a new drug retatrutide (LY3437943), which in addition to stimulating Glucagon-like peptide 1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP) receptors, stimulates glucagon receptors, in subjects with type 2 diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37086147", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37385280", "endSection": "title"}, {"offsetInBeginSection": 156, "offsetInEndSection": 397, "text": "Retatrutide, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors, showed clinically meaningful glucose-lowering and bodyweight-lowering efficacy in a phase 1 study. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37385280", "endSection": "abstract"}, {"offsetInBeginSection": 4779, "offsetInEndSection": 5037, "text": "INTERPRETATION: In people with type 2 diabetes, retatrutide showed clinically meaningful improvements in glycaemic control and robust reductions in bodyweight, with a safety profile consistent with GLP-1 receptor agonists and GIP and GLP-1 receptor agonists.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37385280", "endSection": "abstract"}]}, {"body": "What is the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15913913"], "ideal_answer": "In the study mentioned, the most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients was 1650 mg/m(2) administered daily during the entire course of radiation therapy.", "exact_answer": [["The most appropriate dose of capecitabine in concurrent treatment with radiotherapy for neoadjuvant therapy of locally advanced rectal cancer patients is 1650 mg/m(2) daily."]], "type": "factoid", "id": "66099c01fdcbea915f000023", "snippets": [{"offsetInBeginSection": 587, "offsetInEndSection": 694, "text": "capecitabine was administered daily at a dose of 1650 mg/m(2) during the entire course of radiation therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15913913", "endSection": "abstract"}]}, {"body": "List the methods for pectus excavatum repair?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37417215", "http://www.ncbi.nlm.nih.gov/pubmed/36891368", "http://www.ncbi.nlm.nih.gov/pubmed/34815370", "http://www.ncbi.nlm.nih.gov/pubmed/37451288"], "ideal_answer": "The methods for pectus excavatum repair include the Nuss operation, vacuum bell therapy, and minimally invasive repair of pectus excavatum (MIRPE). The Nuss operation involves the placement of a metal bar to correct the chest wall abnormality. Vacuum bell therapy is a non-invasive treatment modality that uses negative pressure to gradually correct the deformity. MIRPE is a minimally invasive surgical approach that utilizes small incisions and specialized instruments to correct the pectus excavatum deformity.", "exact_answer": [["Nuss operation"], ["Vacuum bell therapy"], ["Minimally invasive repair of pectus excavatum (MIRPE)"], ["Cryoablative therapy"]], "type": "list", "id": "66080f4cfdcbea915f000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Treatment of pectus excavatum with vacuum bell during puberty.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37417215", "endSection": "title"}, {"offsetInBeginSection": 936, "offsetInEndSection": 1115, "text": "This review highlights contemporary management principles of pectus excavatum in the pediatric population, comprising preoperative evaluation, surgical and non-surgical treatment,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36891368", "endSection": "abstract"}, {"offsetInBeginSection": 27, "offsetInEndSection": 244, "text": "ectus excavatum is the most common congenital chest wall anomaly, the hallmark of which is the caved-in appearance of the anterior chest. A growing body of literature exists surrounding methods of surgical correction,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36891368", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 297, "text": "The purpose of this study was to compare 1-year clinical outcomes between patients who underwent a Nuss operation or vacuum bell therapy and to present vacuum bell therapy as a possible alternative treatment modality for patients who prefer non-surgical correction of pectus excavatum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34815370", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 256, "text": "Pectus excavatum deformities are usually repaired with a minimally invasive approach in which a metal bar is used to correct the chest wall abnormality. We aimed to evaluate long-term outcomes and patient satisfaction after surgical correction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37451288", "endSection": "abstract"}]}, {"body": "What is the function of Diphthamide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36802593", "http://www.ncbi.nlm.nih.gov/pubmed/37246715", "http://www.ncbi.nlm.nih.gov/pubmed/35781884", "http://www.ncbi.nlm.nih.gov/pubmed/35817801"], "ideal_answer": "Diphthamide is a post-translational modification of eukaryotic translation elongation factor 2 (EEF2). Its function is to contribute to the functionality of the translational machinery, regulating growth and translation elongation. Loss of diphthamide impairs translational fidelity, leading to increased rates of ribosomal frameshifting and premature termination.", "type": "summary", "id": "66088bbafdcbea915f00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Diphthamide, a post-translationally modified histidine residue of eukaryotic TRANSLATION ELONGATION FACTOR2 (eEF2), ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35817801", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Diphthamide biosynthesis protein 1 (DPH1) is biochemically involved in the first step of diphthamide biosynthesis, a post-translational modification of eukaryotic elongation factor 2 (EEF2). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35781884", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Diphthamide (DPH), a conserved amino acid modification on eukaryotic translation elongation factor eEF2, is synthesized via a complex, multi-enzyme pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37246715", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 283, "text": "It catalyzes the ADP-ribosylation of a post-translationally modified histidine (diphthamide) on eukaryotic elongation factor 2 (eEF2)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36802593", "endSection": "abstract"}]}, {"body": "What disease can be treatment with Bulevirtide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36648369", "http://www.ncbi.nlm.nih.gov/pubmed/36396025", "http://www.ncbi.nlm.nih.gov/pubmed/36377139", "http://www.ncbi.nlm.nih.gov/pubmed/37360907", "http://www.ncbi.nlm.nih.gov/pubmed/37473778", "http://www.ncbi.nlm.nih.gov/pubmed/37345876"], "ideal_answer": "Bulevirtide is used for the treatment of chronic hepatitis D, particularly in patients with co-infection of hepatitis B and D viruses.", "exact_answer": [["Bulevirtide is used for the treatment of chronic hepatitis D."]], "type": "factoid", "id": "65cfdaae1930410b13000025", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The entry inhibitor bulevirtide (BLV) is a new treatment option for patients with chronic hepatitis D virus (HDV) infection and compensated liver disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36648369", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36648369", "endSection": "title"}, {"offsetInBeginSection": 601, "offsetInEndSection": 781, "text": "Bulevirtide, an entry inhibitor, was conditionally approved in July 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and compensated liver disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36396025", "endSection": "abstract"}, {"offsetInBeginSection": 1397, "offsetInEndSection": 1585, "text": "To our knowledge, this is the first reported case of a pembrolizumab-induced exacerbation of hepatitis D and a successful management by application of bulevirtide in the context of cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36377139", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Background & Aims: Bulevirtide (BLV) is a novel antiviral drug licensed for the treatment of chronic hepatitis D.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37360907", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37360907", "endSection": "title"}, {"offsetInBeginSection": 920, "offsetInEndSection": 1203, "text": "Pegylated interferon (off-label use) has long been the only available treatment, although bulevirtide is conditionally approved in some European countries. There are many potential treatments in development, but as yet, there are few effective and safe therapies for HDV infection. I", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37473778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37345876", "endSection": "title"}, {"offsetInBeginSection": 135, "offsetInEndSection": 190, "text": "Bulevirtide inhibits the entry of HDV into hepatocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37345876", "endSection": "abstract"}, {"offsetInBeginSection": 2259, "offsetInEndSection": 2387, "text": "CONCLUSIONS: After 48 weeks of bulevirtide treatment, HDV RNA and ALT levels were reduced in patients with chronic hepatitis D. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37345876", "endSection": "abstract"}]}, {"body": "Are advanced directives an expression of the patient's wishes for future care in case they become cognitively impaired or find themselves in critical condition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37450641", "http://www.ncbi.nlm.nih.gov/pubmed/37444658", "http://www.ncbi.nlm.nih.gov/pubmed/37382889"], "ideal_answer": "Yes, advance directives are a means for patients to express their wishes for future care in the event that they become cognitively impaired or find themselves in critical condition. These directives allow individuals to document their treatment preferences and healthcare decisions in advance, ensuring that their wishes are respected and followed even if they are unable to communicate or make decisions at that time.", "exact_answer": "yes", "type": "yesno", "id": "65f84eadc4010b4d7800004c", "snippets": [{"offsetInBeginSection": 20, "offsetInEndSection": 211, "text": "older patients with advance directives such as a living will, or durable power of attorney for healthcare, are more likely to receive care consistent with their preferences at the end of life", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444658", "endSection": "abstract"}, {"offsetInBeginSection": 875, "offsetInEndSection": 988, "text": "Advance care directives are an important mechanism for documenting treatment preferences in patient care planning", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37382889", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 137, "text": "Advance directives documentation can increase the likelihood that patient's wishes are respected if they become incapacitated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37450641", "endSection": "abstract"}]}, {"body": "Pasteurization kills Mycobacterium tuberculosis from infected cattle.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10835092", "http://www.ncbi.nlm.nih.gov/pubmed/9039448", "http://www.ncbi.nlm.nih.gov/pubmed/7579326"], "ideal_answer": "Yes, pasteurization kills Mycobacterium tuberculosis from infected cattle. Pasteurization is a process of heating milk or other liquids to a specific temperature for a certain period of time to kill harmful bacteria, including Mycobacterium tuberculosis. This helps to prevent the transmission of tuberculosis from infected cattle to humans through the consumption of milk.", "exact_answer": "yes", "type": "yesno", "id": "660c02e1fdcbea915f00002c", "snippets": [{"offsetInBeginSection": 1231, "offsetInEndSection": 1434, "text": "M. bovis infection was recognised as a major public health problem when this organism was transmitted to man via milk from infected cows. The introduction of pasteurization helped eliminate this problem.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7579326", "endSection": "abstract"}, {"offsetInBeginSection": 1038, "offsetInEndSection": 1330, "text": "cut-off in the animal to human chain of infection at two points; the animal source and the ingestion of (now pasteurized) milk. This would suggest that disease in humans is now due to reactivation of previous foci of infection which were acquired when milk pasteurization was not compulsory. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9039448", "endSection": "abstract"}, {"offsetInBeginSection": 1181, "offsetInEndSection": 1570, "text": "M bovis patients were also even more likely to be Hispanic (90.2%), to present with extrapulmonary disease (95.1%), and to be older than 12 months (96.8%).CONCLUSION: These data demonstrate the dramatic impact of this underappreciated cause of zoonotic TB on US children at the Mexican border and underscore the need for cross-collaboration to enforce existing Mexican pasteurization laws.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10835092", "endSection": "abstract"}]}, {"body": "JYNNEOS vaccine is protective against which diseases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36626099", "http://www.ncbi.nlm.nih.gov/pubmed/36752829", "http://www.ncbi.nlm.nih.gov/pubmed/36720271", "http://www.ncbi.nlm.nih.gov/pubmed/36326768", "http://www.ncbi.nlm.nih.gov/pubmed/37498796", "http://www.ncbi.nlm.nih.gov/pubmed/37440743", "http://www.ncbi.nlm.nih.gov/pubmed/37475115"], "ideal_answer": "JYNNEOS vaccine is protective against Monkeypox virus infection.", "exact_answer": [["Monkeypox virus infection"]], "type": "list", "id": "65cfdc561930410b13000026", "snippets": [{"offsetInBeginSection": 897, "offsetInEndSection": 1029, "text": "Monkeypox may be treated with tecovirimat, cidofovir, or brincidofovir, and prevention with the vaccination JYNNEOS is recommended. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36626099", "endSection": "abstract"}, {"offsetInBeginSection": 117, "offsetInEndSection": 335, "text": "This case highlights magnetic resonance (MR) neurography findings in an individual who developed Parsonage-Turner syndrome (PTS) 5 days after monkeypox symptom onset and 12 days after receiving the JYNNEOS vaccination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36752829", "endSection": "abstract"}, {"offsetInBeginSection": 153, "offsetInEndSection": 332, "text": "The smallpox and mpox vaccine (JYNNEOS; Modified Vaccinia Ankara-Bavarian Nordic; MVA-BN), provided as a two-dose regimen, is currently the primary vaccine utilized against mpox. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36720271", "endSection": "abstract"}, {"offsetInBeginSection": 1804, "offsetInEndSection": 1946, "text": "Smallpox vaccines (JYNNEOS [Bavarian Nordic] and ACAM2000 [Emergent Product Development Gaithersburg Inc]) provide immunity against monkeypox.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36326768", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 317, "text": "In August 2022, the Food and Drug Administration authorized JYNNEOS vaccine (modified vaccinia Ankara vaccine, Bavarian Nordic), a 2-dose series used for the prevention of Monkeypox virus infection, to be administered via a dose-sparing intradermal route, in addition to the previously authorized subcutaneous route. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37498796", "endSection": "abstract"}, {"offsetInBeginSection": 643, "offsetInEndSection": 784, "text": " Jynneos (smallpox and mpox vaccine, live, nonreplicating) is a live, attenuated vaccine that is safe for patients who are immunocompromised.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37440743", "endSection": "abstract"}, {"offsetInBeginSection": 153, "offsetInEndSection": 325, "text": "Licensed and approved for mpox, the JYNNEOS vaccine has fewer side-effects than previous smallpox vaccines and has shown immunogenicity against monkeypox in animal models. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37475115", "endSection": "abstract"}]}, {"body": "Is UGT1A1 implicated in Crigler\u2013Najjar syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36936447", "http://www.ncbi.nlm.nih.gov/pubmed/37137832", "http://www.ncbi.nlm.nih.gov/pubmed/37602038", "http://www.ncbi.nlm.nih.gov/pubmed/37585628", "http://www.ncbi.nlm.nih.gov/pubmed/37759499"], "ideal_answer": "Yes, UGT1A1 is implicated in Crigler-Najjar syndrome. Crigler-Najjar syndrome is a rare genetic disease caused by mutations in the UGT1A1 gene, which leads to a deficiency of the Uridine 5'-diphospho-glucuronosyltransferase (UDPGT) enzyme. This enzyme is responsible for the glucuronidation and elimination of unconjugated bilirubin from the body. The absence of functional UGT1A1 enzyme results in severe unconjugated hyperbilirubinemia, which can lead to neurological damage and even death. Therefore, UGT1A1 plays a crucial role in the pathogenesis of Crigler-Najjar syndrome.", "exact_answer": "yes", "type": "yesno", "id": "65cfcc8f1930410b13000018", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Crigler-Najjar syndrome is a rare disorder of bilirubin metabolism caused by uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) mutations characterized by hyperbilirubinemia and jaundice. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36936447", "endSection": "abstract"}, {"offsetInBeginSection": 597, "offsetInEndSection": 829, "text": "Conclusion: The compound heterozygous pathogenic mutations (c.-3279T > G, c.211G > A, and c.1456T > G) at three loci of the UGT1A1 gene may be the feature of the newly discovered CNS-II family genes based on the CNS-II family study.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37137832", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Crigler-Najjar syndrome (CNS) type I is a rare genetic disease caused by mutations in the UGT1A1 gene, resulting in a lack of Uridine 5'-diphospho-glucuronosyltransferase (UDPGT) enzyme. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37602038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "BACKGROUND: Patients with the Crigler-Najjar syndrome lack the enzyme uridine diphosphoglucuronate glucuronosyltransferase 1A1 (UGT1A1), the absence of which leads to severe unconjugated hyperbilirubinemia that can cause irreversible neurologic injury and death. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37585628", "endSection": "abstract"}, {"offsetInBeginSection": 264, "offsetInEndSection": 430, "text": "A defect in the UGT1A1 enzyme-encoding gene, which is directly responsible for bilirubin conjugation, can cause Crigler-Najjar syndrome (CNS) and Gilbert's syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37759499", "endSection": "abstract"}]}, {"body": "Is surgical resection an appropriate treatment over immunotherapy in MSI-H locally advanced rectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35371084"], "ideal_answer": "Surgical resection is the standard treatment for locally advanced rectal cancer. However, in patients with MSI-H (microsatellite instability-high) locally advanced rectal cancer, immunotherapy has shown promising results. The use of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, has been approved by the FDA for the treatment of MSI-H metastatic colorectal cancer. There is growing interest in using immunotherapy as neoadjuvant therapy for MSI-H locally advanced rectal cancer, which may change the current approaches to treatment. Further research and clinical trials are needed to determine the optimal treatment strategy for these patients.", "exact_answer": "no", "type": "yesno", "id": "65f779edc4010b4d78000039", "snippets": [{"offsetInBeginSection": 1713, "offsetInEndSection": 1807, "text": "Our team also proposes a new organ-preservation strategy for patients with MSI-H/dMMR low LARC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35371084", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 357, "text": "patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) LACRC receive little benefit from neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35371084", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence and metastasis, although neoadjuvant therapy may provide some benefit", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35371084", "endSection": "abstract"}]}, {"body": "What molecular subtypes of colon cancer are associated to smoking?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20587792"], "ideal_answer": "Cigarette smoking is associated with the MSI-high, CIMP-positive, and BRAF mutation-positive subtypes of colorectal cancer. These findings suggest that smoking may contribute to epigenetic modifications and play a role in the development of these specific molecular subtypes of colon cancer.", "exact_answer": [["MSI-high"], ["CIMP-positive"], ["BRAF mutation-positive"]], "type": "list", "id": "660998d1fdcbea915f000013", "snippets": [{"offsetInBeginSection": 2679, "offsetInEndSection": 2800, "text": "cigarette smoking was associated with the MSI-high, CIMP-positive, and BRAF mutation-positive colorectal cancer subtypes,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587792", "endSection": "abstract"}]}, {"body": "Without immunization, rabies is a lethal disease.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35931921", "http://www.ncbi.nlm.nih.gov/pubmed/36343866", "http://www.ncbi.nlm.nih.gov/pubmed/37728394"], "ideal_answer": "Yes, without immunization, rabies is a lethal disease. Rabies is an acute infectious disease caused by a lyssavirus infection. It is primarily transmitted to humans through the bite of an infected animal, most commonly dogs. Rabies affects the central nervous system and is almost always fatal once symptoms appear. Immunization, specifically through vaccination, is the most effective way to prevent rabies infection and its deadly consequences.", "exact_answer": "yes", "type": "yesno", "id": "660d6a97fdcbea915f00003c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Rabies is a lethal zoonotic disease mainly transmitted to humans by dog bites", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35931921", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 89, "text": "Rabies is an acute lethal infectious disease caused by a lyssavirus infection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36343866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 38, "text": "Rabies, a lethal zoonotic encephalitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37728394", "endSection": "abstract"}]}, {"body": "Cancer risk in transgender individuals.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36757703", "http://www.ncbi.nlm.nih.gov/pubmed/31027551"], "ideal_answer": "Transgender and gender-diverse individuals may have an altered risk of certain types of cancer due to exposure to sex hormones. They have a high prevalence of tobacco consumption, alcohol use, and infection with HPV and HIV. They are less likely to adhere to cancer screening programs and have a higher incidence of HIV- and HPV-associated cancers. Barriers to healthcare access and lack of knowledge among healthcare practitioners contribute to disparities in cancer prevention and care for transgender individuals.", "type": "summary", "id": "660d70b3fdcbea915f00003f", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 192, "text": "Transgender and gender-diverse individuals face unique challenges, including barriers to health care access and inequities in treatment, that may influence cancer risk and outcomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36757703", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 797, "text": "transgender and gender-diverse people had a high prevalence of tobacco consumption and alcohol use and high rates of infection with human papillomavirus (HPV) and HIV", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36757703", "endSection": "abstract"}, {"offsetInBeginSection": 799, "offsetInEndSection": 959, "text": "Transgender and gender-diverse individuals were less likely to adhere to cancer screening programs and had a higher incidence of HIV- and HPV-associated cancers", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36757703", "endSection": "abstract"}, {"offsetInBeginSection": 1290, "offsetInEndSection": 1523, "text": "Discrimination, discomfort caused by gender-labeled oncological services, stigma, and lack of cultural sensitivity of health care practitioners were other barriers met by transgender and gender-diverse persons in the oncology setting", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36757703", "endSection": "abstract"}, {"offsetInBeginSection": 1551, "offsetInEndSection": 1679, "text": "The findings suggest that transgender and gender-diverse peoples' needs in the cancer care continuum are not optimally addressed", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36757703", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 391, "text": "Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31027551", "endSection": "abstract"}]}, {"body": "Is One-carbon (1C)  metabolism associated with folate?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36822494", "http://www.ncbi.nlm.nih.gov/pubmed/37665322", "http://www.ncbi.nlm.nih.gov/pubmed/35508111"], "ideal_answer": "Yes, one-carbon (1C) metabolism is associated with folate. Folate is an essential cofactor in the 1C metabolic pathway, which involves the transfer of 1C units to support nucleotide biosynthesis, amino acid metabolism, purine and thymidylate synthesis, and DNA methylation. Folate plays a crucial role in providing methyl groups required for DNA and histone methylation, and is involved in the maintenance of self-renewal in stem cells. Therefore, folate is closely linked to the regulation of 1C metabolism.", "exact_answer": "yes", "type": "yesno", "id": "66081d61fdcbea915f000007", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 132, "text": "Folate (FA) is an essential cofactor in the one-carbon (1C) metabolic pathway and participates in amino acid metabolism,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36822494", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "One-carbon/folate (1C) metabolism supplies methyl groups required for DNA and histone methylation, and is involved in the maintenance of self-renewal in stem cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37665322", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The folic acid cycle mediates the transfer of one-carbon (1C) units to support nucleotide biosynthesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35508111", "endSection": "abstract"}]}, {"body": "Should corticosteroids be considered as adjunctive therapy in paediatric sepsis management?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35307800"], "ideal_answer": "Based on current guidelines and available evidence, corticosteroids should be considered as adjunctive therapy in pediatric sepsis management in specific cases, such as children with fluid and vasoactive-inotropic resistant shock, but their routine use is not recommended due to limited evidence and potential adverse effects.", "exact_answer": "no", "type": "yesno", "id": "660c49f4fdcbea915f000034", "snippets": [{"offsetInBeginSection": 940, "offsetInEndSection": 1195, "text": "Controversy remains regarding resuscitation fluid volume and type, antibiotic choices depending upon infectious risks in the patient's community, and adjunctive therapies such as vitamin C, corticosteroids, intravenous immunoglobulin, and methylene blue. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35307800", "endSection": "abstract"}]}, {"body": "List of attenuated viral vaccines still in use.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25864107", "http://www.ncbi.nlm.nih.gov/pubmed/37286215", "http://www.ncbi.nlm.nih.gov/pubmed/37309028"], "ideal_answer": "Some examples of attenuated viral vaccines still in use include the measles, mumps, and rubella (MMR) vaccine, the varicella (chickenpox) vaccine, the yellow fever vaccine, the oral polio vaccine, and the rotavirus vaccine.", "exact_answer": [["Measles"], ["Mumps"], ["Rubella"], ["Varicella (chickenpox)"], ["Yellow fever"]], "type": "list", "id": "660d2299fdcbea915f000038", "snippets": [{"offsetInBeginSection": 141, "offsetInEndSection": 149, "text": "Smallpox", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25864107", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 238, "text": "measles", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25864107", "endSection": "abstract"}, {"offsetInBeginSection": 183, "offsetInEndSection": 196, "text": "poliomyelitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25864107", "endSection": "abstract"}, {"offsetInBeginSection": 2249, "offsetInEndSection": 2276, "text": "live attenuated MMR vaccine", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37286215", "endSection": "abstract"}, {"offsetInBeginSection": 21, "offsetInEndSection": 88, "text": "live vaccines such as measles, mumps, rubella, and varicella (MMRV)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37309028", "endSection": "abstract"}]}, {"body": "What is the association between statins and stroke?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34154390", "http://www.ncbi.nlm.nih.gov/pubmed/36706354"], "ideal_answer": "Statins have been shown to increase the risk of hemorrhagic stroke in patients with a first cerebrovascular event. However, the recently available PCSK9Is (proprotein convertase subtilisin kexin 9 inhibitors) have shown potentially less hemorrhagic propensity. Therefore, PCSK9Is may be a preferred lipid-lowering medication class in patients with elevated hemorrhagic stroke risk, including those with prior hemorrhagic stroke.", "type": "summary", "id": "660d2a50fdcbea915f00003a", "snippets": [{"offsetInBeginSection": 23, "offsetInEndSection": 125, "text": " Statins were shown to increase hemorrhagic stroke (HS) in patients with a first cerebrovascular event", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34154390", "endSection": "abstract"}, {"offsetInBeginSection": 2046, "offsetInEndSection": 2077, "text": "Statins increase the risk of HS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34154390", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 176, "text": "benefit of statin for stroke is debatable as regular statin users may suffer from myalgia, statin-associated myopathy (SAM), and rarely rhabdomyolysis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36706354", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of Mirvetuximab Soravtansine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36736157", "http://www.ncbi.nlm.nih.gov/pubmed/36716407", "http://www.ncbi.nlm.nih.gov/pubmed/37023499", "http://www.ncbi.nlm.nih.gov/pubmed/37229642", "http://www.ncbi.nlm.nih.gov/pubmed/36656533", "http://www.ncbi.nlm.nih.gov/pubmed/37102083"], "ideal_answer": "Mirvetuximab soravtansine is a first-in-class antibody-drug conjugate (ADC) that targets folate receptor alpha (FR\u03b1). It is comprised of a folate receptor \u03b1 (FR\u03b1) directed antibody conjugated to a microtubule inhibitor via a cleavable linker.", "type": "summary", "id": "65cf6c301930410b13000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36736157", "endSection": "title"}, {"offsetInBeginSection": 155, "offsetInEndSection": 253, "text": "Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor \u03b1 (FR\u03b1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36716407", "endSection": "abstract"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1127, "text": "Consequently, ADCs are gaining traction in gynecologic cancers with the recent US Food and Drug Administration approvals of tisotumab vedotin in cervical cancer and mirvetuximab soravtansine in ovarian cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37023499", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 732, "text": "In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FR\u03b1), received US Food and Drug Administration (FDA) accelerated approval in November 2022 after data from the single-arm phase III SORAYA trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37229642", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere\u2122) is an antibody-drug conjugate (ADC), which is comprised of a folate receptor \u03b1 (FR\u03b1) directed antibody conjugated to a microtubule inhibitor via a cleavable linker. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36656533", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 336, "text": "Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FR\u03b1) and is indicated for the treatment of adult patients with FR\u03b1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37102083", "endSection": "abstract"}]}, {"body": "What are common complications of prematurity for babies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36829980"], "ideal_answer": "Common complications of prematurity for babies include respiratory distress syndrome, bronchopulmonary dysplasia, retinopathy of prematurity, periventricular leukomalacia, necrotizing enterocolitis, and neonatal sepsis. These complications are often associated with oxidative stress, which can lead to further damage and exacerbate the clinical burden. Understanding the underlying pathophysiological mechanisms can help in developing strategies to prevent or reduce the development of these conditions.", "exact_answer": [["Respiratory distress syndrome"], ["Bronchopulmonary dysplasia"], ["Retinopathy of prematurity"], ["Periventricular leukomalacia"], ["Necrotizing enterocolitis"]], "type": "list", "id": "660c0a85fdcbea915f000030", "snippets": [{"offsetInBeginSection": 1188, "offsetInEndSection": 1338, "text": "respiratory distress, bronchopulmonary dysplasia, retinopathy of prematurity, periventricular leukomalacia, necrotizing enterocolitis, neonatal sepsis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36829980", "endSection": "abstract"}]}, {"body": "What is a basket trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35993875", "http://www.ncbi.nlm.nih.gov/pubmed/36163614"], "ideal_answer": "A basket trial is a type of clinical trial design that evaluates the effectiveness of a new treatment in multiple patient subgroups or cancer types under one protocol. It allows for the simultaneous assessment of treatment effects in different patient populations, often based on specific biomarkers or genetic mutations. This design enables researchers to study the efficacy of a treatment across various diseases or subtypes, potentially leading to more personalized and targeted therapies.", "type": "summary", "id": "66088f67fdcbea915f00000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Basket trials are increasingly used for the simultaneous evaluation of a new treatment in various patient subgroups under one overarching protocol. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35993875", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The phase II basket trial in oncology is a novel design that enables the simultaneous assessment of treatment effects of one anti-cancer targeted agent in multiple cancer types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36163614", "endSection": "abstract"}]}, {"body": "Which initial chemotherapy regimen is the most appropriate in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37174033", "http://www.ncbi.nlm.nih.gov/pubmed/34963563"], "ideal_answer": "The most appropriate initial chemotherapy regimen in Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer patients is mFOLFOXIRI (modified FOLFOXIRI). This regimen has been shown to improve the pathological complete response (pCR) rate, reduce the rate of distant metastasis, and improve survival outcomes compared to other regimens, such as mFOLFOX6. However, it is important to consider individual patient factors and discuss treatment options with a multidisciplinary team to determine the most suitable regimen for each patient.", "exact_answer": [["mFOLFOXIRI"]], "type": "factoid", "id": "65f7785dc4010b4d78000033", "snippets": [{"offsetInBeginSection": 1243, "offsetInEndSection": 1449, "text": "A plethora of potential chemotherapy schedules are available around the radiotherapy component, which include preoperative induction or consolidation with a range of options (FOLFOXIRI, FOLFOX, or CAPEOX,) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37174033", "endSection": "abstract"}, {"offsetInBeginSection": 1606, "offsetInEndSection": 1832, "text": "Neoadjuvant mFOLFOXIRI regimens improved pCR rate and survival outcome, reduced the rate of distant metastasis and anastomotic fistula when comparing with propensity-score matched controls of mFOLFOX6 neoadjuvant chemotherapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34963563", "endSection": "abstract"}]}, {"body": "Is transdermal glyceryl trinitrate effective for stroke?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37290930", "http://www.ncbi.nlm.nih.gov/pubmed/37564156", "http://www.ncbi.nlm.nih.gov/pubmed/30738649"], "ideal_answer": "Based on the information provided, the use of transdermal glyceryl trinitrate (GTN) in the ultra-acute phase of stroke did not improve clinical outcomes in patients with confirmed ischemic stroke. The study did not find a significant difference in the modified Rankin Scale (mRS) scores at day 90 or day 365 between the GTN group and the sham group. Therefore, based on this study, transdermal GTN is not considered effective for stroke.", "exact_answer": "no", "type": "yesno", "id": "65d136081930410b1300003a", "snippets": [{"offsetInBeginSection": 1690, "offsetInEndSection": 1942, "text": "CONCLUSIONS: In patients who had an ischaemic stroke, ultra-acute administration of transdermal GTN in the ambulance did not improve clinical outcomes in a population with more clinical and radiological frailty than seen in previous in-hospital trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37290930", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Background: The Rapid Intervention with Glyceryl Trinitrate in Hypertensive Stroke Trial-2 (RIGHT-2) reported no overall treatment difference between glyceryl trinitrate (GTN) and sham at day 90. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37564156", "endSection": "abstract"}, {"offsetInBeginSection": 1452, "offsetInEndSection": 1595, "text": "Conclusion: At 1\u2009year post randomisation, dependency did not differ between GTN and sham treatment in either the target population or overall. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37564156", "endSection": "abstract"}, {"offsetInBeginSection": 2858, "offsetInEndSection": 2995, "text": "INTERPRETATION: Prehospital treatment with transdermal GTN does not seem to improve functional outcome in patients with presumed stroke. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30738649", "endSection": "abstract"}]}, {"body": "What is the mechanism by which the microbiota module the effectiveness of chemotherapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24264989"], "ideal_answer": "The microbiota modulates the effectiveness of chemotherapy by influencing the functions of myeloid-derived cells in the tumor microenvironment. Disruption of the microbiota impairs the response of tumor-infiltrating myeloid-derived cells to chemotherapy, resulting in deficient production of reactive oxygen species and cytotoxicity. An intact commensal microbiota is necessary for optimal responses to chemotherapy.", "type": "summary", "id": "65f77919c4010b4d78000036", "snippets": [{"offsetInBeginSection": 275, "offsetInEndSection": 412, "text": "disruption of the microbiota impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24264989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24264989", "endSection": "abstract"}]}, {"body": "What channel is targeted by VX-548?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37530822"], "ideal_answer": "VX-548 targets the NaV1.8 voltage-gated sodium channel, which is expressed in peripheral nociceptive neurons and plays a role in transmitting nociceptive signals.", "exact_answer": [["VX-548 targets the NaV1.8 voltage-gated sodium channel."]], "type": "factoid", "id": "65cfd02e1930410b1300001c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822", "endSection": "title"}, {"offsetInBeginSection": 148, "offsetInEndSection": 259, "text": "The effect of VX-548, an oral, highly selective inhibitor of NaV1.8, on control of acute pain is being studied.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37530822", "endSection": "abstract"}]}, {"body": "Amyloid-\u03b2 is associated with what diseases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37488848", "http://www.ncbi.nlm.nih.gov/pubmed/37905874", "http://www.ncbi.nlm.nih.gov/pubmed/37652560"], "ideal_answer": "Amyloid-\u03b2 is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy.", "exact_answer": [["Alzheimer's disease"], ["Lewy body disease"], ["Multiple system atrophy"], ["Frontotemporal lobar degeneration-TDP-43"], ["Progressive supranuclear palsy"]], "type": "list", "id": "66097092fdcbea915f000010", "snippets": [{"offsetInBeginSection": 49, "offsetInEndSection": 388, "text": " amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer's disease (AD). We analyzed A\u03b2 deposition in the temporal cortex and striatum in 116 autopsies, including Lewy body disease (LBD; N\u2009=\u200951), multiple system atrophy (MSA; N\u2009=\u200910), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP; N\u2009=\u200916), and progressive supranuclear palsy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37652560", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 985, "text": "Recent studies have indicated associations between aberrant behavior of amyloid-beta and tau proteins and various neurological diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, these proteins have been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37905874", "endSection": "abstract"}]}, {"body": "Are senolytics used to treat cardiovascular disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35015342", "http://www.ncbi.nlm.nih.gov/pubmed/37747577", "http://www.ncbi.nlm.nih.gov/pubmed/32979174", "http://www.ncbi.nlm.nih.gov/pubmed/34237321"], "ideal_answer": "Yes, senolytics are used to treat cardiovascular disease. Senolytics are compounds designed to eliminate senescent cells within the tissues. Accumulation of senescent cells in the heart contributes to various age-related pathologies. Senolytics, such as dasatinib and quercetin, have shown promise in preventing the progression of myocardial damage in cardiovascular disease. These compounds target components of anti-apoptotic pathways expressed by senescent cells, inducing apoptosis and eliminating the senescent cells. The use of senolytics represents a promising field for finding accessible and safe therapies for cardiovascular disease treatment.", "exact_answer": "yes", "type": "yesno", "id": "66088ddbfdcbea915f00000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Therapeutic opportunities for senolysis in cardiovascular disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015342", "endSection": "title"}, {"offsetInBeginSection": 737, "offsetInEndSection": 966, "text": "These findings coupled with the emergence of senolytic therapies, to target and eliminate senescent cells, have provided fascinating new avenues for management of several age-related cardiovascular diseases with high prevalence. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015342", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Quercetin and dasatinib, two powerful senolytics in age-related cardiovascular disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37747577", "endSection": "title"}, {"offsetInBeginSection": 303, "offsetInEndSection": 481, "text": "In recent years, the use and study of senolytics increased, representing a promising field for finding accessible and safe therapies for cardiovascular disease (CVD) treatment. T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37747577", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Therapeutic Potential of Senolytics in Cardiovascular Disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32979174", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34237321", "endSection": "title"}]}, {"body": "Can Rozanolixizumab be used for treatment of multiple sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37059507", "http://www.ncbi.nlm.nih.gov/pubmed/37287352", "http://www.ncbi.nlm.nih.gov/pubmed/37166675", "http://www.ncbi.nlm.nih.gov/pubmed/37602255", "http://www.ncbi.nlm.nih.gov/pubmed/37656420", "http://www.ncbi.nlm.nih.gov/pubmed/37735554", "http://www.ncbi.nlm.nih.gov/pubmed/37962198", "http://www.ncbi.nlm.nih.gov/pubmed/34735735"], "ideal_answer": "No, Rozanolixizumab is not currently approved for the treatment of multiple sclerosis. It is being developed for the treatment of autoimmune diseases, including generalized myasthenia gravis, leucine-rich glioma-inactivated 1 autoimmune encephalitis, myelin oligodendrocyte glycoprotein antibody disease, and severe fibromyalgia syndrome. However, its use in multiple sclerosis has not been studied or approved.", "exact_answer": "no", "type": "yesno", "id": "65d1350f1930410b13000038", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059507", "endSection": "title"}, {"offsetInBeginSection": 3136, "offsetInEndSection": 3349, "text": "INTERPRETATION: Rozanolixizumab showed clinically meaningful improvements in patient-reported and investigator-assessed outcomes in patients with generalised myasthenia gravis, for both 7 mg/kg and 10 mg/kg doses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059507", "endSection": "abstract"}, {"offsetInBeginSection": 3508, "offsetInEndSection": 3623, "text": "Rozanolixizumab represents a potential additional treatment option for patients with generalised myasthenia gravis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059507", "endSection": "abstract"}, {"offsetInBeginSection": 816, "offsetInEndSection": 1023, "text": "Additionally, several international clinical trials (e.g., rituximab, inebilizumab, ocrelizumab, bortezomib, and rozanolixizumab) for AE treatments, including anti-NMDAR encephalitis, have been implemented. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37287352", "endSection": "abstract"}, {"offsetInBeginSection": 726, "offsetInEndSection": 906, "text": "Post hoc analyses of the MG0002 study, a Phase 2a clinical trial of rozanolixizumab in adults with moderate to severe generalized MG, included correlation and Rasch model analyses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37166675", "endSection": "abstract"}, {"offsetInBeginSection": 1192, "offsetInEndSection": 1379, "text": "Efgartigimod is already approved for the treatment of generalized MG, rozanolixizumab is under review by health authorities, and phase 3 trials of nipocalimab and batoclimab are underway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37602255", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 728, "text": "Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO\u00ae) is a high affinity humanized immunoglobulin G4 monoclonal antibody directed against human neonatal Fc receptor (FcRn). Administered subcutaneously, it is being developed by UCB Pharma for the treatment of autoimmune diseases and received its first approval on 27\u00a0June 2023 in the USA for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive. Rozanolixizumab is the first agent to be approved in the USA for both anti-AChR and anti-MuSK antibody-positive gMG. A regulatory assessment of rozanolixizumab for the treatment of gMG is currently underway in the EU and Japan.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37656420", "endSection": "abstract"}, {"offsetInBeginSection": 934, "offsetInEndSection": 1126, "text": "This article summarizes the milestones in the development of rozanolixizumab leading to this first approval for the treatment of gMG in adults who are anti-AChR or anti-MuSK antibody positive.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37656420", "endSection": "abstract"}]}, {"body": "In what part of the cell would a SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) be found", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37465385", "http://www.ncbi.nlm.nih.gov/pubmed/36750663", "http://www.ncbi.nlm.nih.gov/pubmed/37027300"], "ideal_answer": "SNARE proteins, also known as Soluble N-ethylmaleimide-sensitive factor attachment protein receptors, are primarily found in the cytoplasm of cells.", "exact_answer": [["SNARE proteins are primarily found in the cytoplasm of cells."]], "type": "factoid", "id": "66088d66fdcbea915f00000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (R-SNAREs) mainly promoted the assembly of the SNARE complex to drive the final membrane fusion step of membrane transport", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465385", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The dynamic assembly of the Synaptic-soluble N-ethylmaleimide-sensitive factor Attachment REceptor (SNARE) complex is crucial to understand membrane fusion. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36750663", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The AAA+ NSF complex is responsible for SNARE complex disassembly both before and after membrane fusion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37027300", "endSection": "abstract"}]}, {"body": "What is the significance of Acute pancreatitis-induced splanchnic vein thrombosis", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35867193", "http://www.ncbi.nlm.nih.gov/pubmed/37210302", "http://www.ncbi.nlm.nih.gov/pubmed/37933195", "http://www.ncbi.nlm.nih.gov/pubmed/33180323", "http://www.ncbi.nlm.nih.gov/pubmed/26513113"], "ideal_answer": "Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is an important complication of acute pancreatitis. It can lead to severe gastrointestinal hemorrhage, bowel ischemic necrosis, and liver failure, resulting in poor prognosis. The mechanism of APISVT is uncertain, and there is no general consensus on its management. Anticoagulation therapy has shown promise in improving thrombus recanalization and reducing complications and mortality, but more research is needed to establish its effectiveness and safety.", "type": "summary", "id": "66088cccfdcbea915f00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Deep Venous Thrombosis in Acute Pancreatitis Is Associated with High Mortality", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35867193", "endSection": "title"}, {"offsetInBeginSection": 10, "offsetInEndSection": 127, "text": ": Splanchnic vein thrombosis (SVT) is a well-recognised though little-studied complication in acute pancreatitis (AP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37210302", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "Acute pancreatitis-induced splanchnic vein thrombosis (APISVT) is an important sequela complication of acute pancreatitis, which may cause poor prognosis, such as severe gastrointestinal hemorrhage, bowel ischemic necrosis and liver failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37933195", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 160, "text": "Splanchnic vein thrombosis (SVT) is an uncommon but potentially life-threatening disease usually related to different underlying clinical conditions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33180323", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 98, "text": "Splanchnic vein thrombosis (SVT) is a potentially severe complication of pancreatitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26513113", "endSection": "abstract"}]}, {"body": "Is the use of Bevacizumab indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18854571"], "ideal_answer": "Yes, the use of Bevacizumab is indicated after progression to a previous regimen with Bevacizumab in advanced colorectal cancer patients. A large observational study (BRiTE) showed that continuing Bevacizumab treatment beyond initial disease progression (BBP) was strongly and independently associated with improved survival in patients with metastatic colorectal cancer (mCRC). The study reported a longer-than-expected overall survival of 25.1 months in patients who received Bevacizumab. The results suggest that continued vascular endothelial growth factor inhibition with Bevacizumab could play an important role in improving the overall success of therapy for patients with mCRC.", "exact_answer": "yes", "type": "yesno", "id": "66099af7fdcbea915f000020", "snippets": [{"offsetInBeginSection": 1608, "offsetInEndSection": 1869, "text": "These results from a large, prospective, observational study suggest that continued vascular endothelial growth factor inhibition with bevacizumab beyond initial PD could play an important role improving the overall success of therapy for patients who have mCRC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18854571", "endSection": "abstract"}]}, {"body": "Which gene mutations confer acquired resistance to anti-EGFR therapy in advance colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31653970", "http://www.ncbi.nlm.nih.gov/pubmed/36117191"], "ideal_answer": "The genomic analysis revealed that KRAS K117N and A146T mutations, as well as BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications, confer acquired resistance to anti-EGFR therapy in advanced colorectal cancer.", "exact_answer": [["NCOA4-RET"], ["LMNA-NTRK1"], ["NRG1"], ["GNAS"], ["KRAS K117N"]], "type": "list", "id": "65f7764fc4010b4d7800002f", "snippets": [{"offsetInBeginSection": 653, "offsetInEndSection": 813, "text": "In cetuximab-sensitive patients, we found KRAS K117N and A146T mutations in addition to BRAF V600E, AKT1 E17K, PIK3CA E542K, and FGFR1 or ERBB2 amplifications. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31653970", "endSection": "abstract"}, {"offsetInBeginSection": 495, "offsetInEndSection": 603, "text": "ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117191", "endSection": "abstract"}]}, {"body": "Impact of pollution on asthma.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31916265", "http://www.ncbi.nlm.nih.gov/pubmed/32867076"], "ideal_answer": "Air pollution, both outdoor and indoor, has a negative impact on asthma outcomes. Exposure to outdoor pollutants can induce asthma symptoms, exacerbations, and decrease lung function. Traffic-related air pollution, nitrogen dioxide, and second-hand smoking are significant risk factors for asthma development in children. Active tobacco smoking is associated with poorer asthma control, while exposure to second-hand smoke increases the risk of asthma exacerbations and respiratory symptoms. Other indoor pollutants such as heating sources and molds can also negatively impact asthma. Global measures to reduce exposure to air pollutants are needed to improve asthma outcomes and management.", "type": "summary", "id": "660d27e3fdcbea915f000039", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Air pollution and climate change have a significant impact on human health and well-being and contribute to the onset and aggravation of allergic rhinitis and asthma among other chronic respiratory diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31916265", "endSection": "abstract"}, {"offsetInBeginSection": 382, "offsetInEndSection": 533, "text": "high exposure to indoor allergens (house dust mites, pets, molds, etc), tobacco smoke, and other pollutants, which have an impact on respiratory health", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31916265", "endSection": "abstract"}, {"offsetInBeginSection": 535, "offsetInEndSection": 709, "text": "Outdoor air pollution derived from traffic and other human activities not only has a direct negative effect on human health but also enhances the allergenicity of some plants", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31916265", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1064, "text": "effects of indoor air pollution, outdoor air pollution, and subsequent climate change on asthma and allergic rhinitis in children and adults", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31916265", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 260, "text": "air pollution has a negative impact on asthma outcomes in both adult and pediatric populations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32867076", "endSection": "abstract"}, {"offsetInBeginSection": 330, "offsetInEndSection": 387, "text": "effect of various outdoor and indoor pollutants on asthma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32867076", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 671, "text": "Traffic-related air pollution, nitrogen dioxide and second-hand smoking (SHS) exposures represent significant risk factors for asthma development in children", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32867076", "endSection": "abstract"}, {"offsetInBeginSection": 787, "offsetInEndSection": 890, "text": "Exposure to outdoor pollutants can induce asthma symptoms, exacerbations and decreases in lung function", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32867076", "endSection": "abstract"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1177, "text": "indoor pollutants such as heating sources and molds can also negatively impact the course of asthma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32867076", "endSection": "abstract"}]}, {"body": "What are atypical symptoms of gluten allergy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37546121", "http://www.ncbi.nlm.nih.gov/pubmed/33573512"], "ideal_answer": "Atypical symptoms of gluten allergy, such as in the case of celiac disease, can include hematological abnormalities like extreme thrombocytosis secondary to severe anemia, paraesthesia, numbness in the hands and feet, marked thinness, and mild electrolyte imbalance. These symptoms may present without the typical gastrointestinal symptoms commonly associated with gluten allergy. Other atypical symptoms can include irritability, dermatitis herpetiformis, alopecia, and intussusception. It is important for healthcare professionals to have a high index of suspicion for atypical presentations of gluten allergy to ensure early diagnosis and appropriate management.", "exact_answer": [["Paraesthesia"], ["numbness in hands and feet"], ["Extreme thrombocytosis"], ["Severe anemia"], ["Mild electrolyte imbalance"]], "type": "list", "id": "660d2d6afdcbea915f00003b", "snippets": [{"offsetInBeginSection": 225, "offsetInEndSection": 355, "text": "atypical presentations can pose diagnostic challenges, particularly when hematological abnormalities are the primary manifestation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546121", "endSection": "abstract"}, {"offsetInBeginSection": 425, "offsetInEndSection": 557, "text": "paraesthesia, numbness in her hands and feet, marked thinness, extreme thrombocytosis, severe anemia, and mild electrolyte imbalance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546121", "endSection": "abstract"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1039, "text": "CD as a potential cause for atypical hematological manifestations, such as extreme thrombocytosis secondary to severe anemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546121", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 476, "text": "stunted growth", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33573512", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 492, "text": "underweight", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33573512", "endSection": "abstract"}, {"offsetInBeginSection": 494, "offsetInEndSection": 580, "text": "Irritability, anaemia, rickets, dermatitis herpetiformis, alopecia and intussusception", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33573512", "endSection": "abstract"}]}, {"body": "What is Tagraxofusp?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36951152", "http://www.ncbi.nlm.nih.gov/pubmed/37846131", "http://www.ncbi.nlm.nih.gov/pubmed/38052038"], "ideal_answer": "Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). It is a CD123-targeting drug approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and other CD123-positive myeloid malignancies.", "type": "summary", "id": "660a8fc4fdcbea915f000027", "snippets": [{"offsetInBeginSection": 477, "offsetInEndSection": 562, "text": "tagraxofusp, a CD123-targeting drug consisting of the ligand for CD123, interleukin 3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36951152", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37846131", "endSection": "abstract"}, {"offsetInBeginSection": 104, "offsetInEndSection": 309, "text": "Tagraxofusp (TAG), recombinant interleukin-3 fused to a truncated diphtheria toxin payload, is a first-in-class drug targeting CD123 approved for treatment of blastic plasmacytoid dendritic cell neoplasm. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38052038", "endSection": "abstract"}]}, {"body": "Why is the clinical benefit of EGFR inhibitors different in right and left colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34026368", "http://www.ncbi.nlm.nih.gov/pubmed/30116425"], "ideal_answer": "The clinical benefit of EGFR inhibitors differs in right and left colorectal cancer due to the differences in molecular characteristics and histology between these tumor entities. Right-sided colorectal cancer (RCRC) commonly exhibits mutations in the DNA mismatch repair pathway and has a flat histology, while left-sided colorectal cancer (LCRC) is characterized by chromosomal instability pathway-related mutations and a polypoid-like morphology. LCRC patients benefit more from adjuvant chemotherapies and targeted therapies such as anti-EGFR therapy, while RCRC patients do not respond well to conventional chemotherapies but show promising results with immunotherapies due to their high antigenic load.", "type": "summary", "id": "65f773cdc4010b4d78000026", "snippets": [{"offsetInBeginSection": 293, "offsetInEndSection": 754, "text": "Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30116425", "endSection": "abstract"}, {"offsetInBeginSection": 1279, "offsetInEndSection": 1878, "text": " The analysis of the immune microenvironment showed that immune infiltration was more common in RCC than LCC. The results of differential gene analysis showed that there were 360 differentially expressed genes, with 142 upregulated genes in LCC and 218 upregulated genes in RCC. The mutation frequency of RCC was generally higher than that of LCC. BRAF and KRAS gene mutations were the dominant genes mutations in RCC, and they had a strong mutual exclusion with APC, while APC gene mutation was the dominant gene mutation in LCC. This suggests that the molecular mechanisms of RCC and LCC differed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34026368", "endSection": "abstract"}]}, {"body": "Can lactate levels predict mortality in paediatric sepsis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34612847"], "ideal_answer": "Yes, lactate levels can predict mortality in pediatric sepsis. According to the study mentioned in the given context, serum lactate levels demonstrated a significant and consistent association with mortality in children with sepsis, severe sepsis, or septic shock. Elevated lactate levels indicate tissue hypoperfusion and are a marker of organ dysfunction. Higher lactate levels are associated with a higher risk of mortality in pediatric sepsis.", "exact_answer": "yes", "type": "yesno", "id": "660c44f7fdcbea915f000033", "snippets": [{"offsetInBeginSection": 1429, "offsetInEndSection": 1862, "text": " In children with sepsis/severe sepsis/septic shock, chronic conditions, oncologic diagnosis, use of vasoactive/inotropic agents, mechanical ventilation, serum lactate, platelet count, fibrinogen, procalcitonin, multi-organ dysfunction syndrome, Pediatric Logistic Organ Dysfunction score, Pediatric Index of Mortality-3, and Pediatric Risk of Mortality score each demonstrated significant and consistent associations with mortality.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34612847", "endSection": "abstract"}]}, {"body": "Is Depatuxizumab mafodotin effective for glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37257422", "http://www.ncbi.nlm.nih.gov/pubmed/35849035", "http://www.ncbi.nlm.nih.gov/pubmed/37085569", "http://www.ncbi.nlm.nih.gov/pubmed/34050676", "http://www.ncbi.nlm.nih.gov/pubmed/33601293", "http://www.ncbi.nlm.nih.gov/pubmed/34204877"], "ideal_answer": "Based on the available evidence, the effectiveness of Depatuxizumab mafodotin (Depatux-M) for glioblastoma is still under investigation. While some studies have shown encouraging clinical benefits, such as improved progression-free survival, other studies have not demonstrated a significant improvement in overall survival. Additionally, Depatux-M has been associated with ocular toxicity, which may limit its use. Further research is needed to determine the true efficacy and safety profile of Depatux-M in the treatment of glioblastoma.", "exact_answer": "yes", "type": "yesno", "id": "65d132101930410b13000035", "snippets": [{"offsetInBeginSection": 1649, "offsetInEndSection": 1805, "text": "RESULTS: The UNITE study was stopped early after interim analysis of separate phase III trial showed no difference in survival from depatuxizumab mafodotin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37257422", "endSection": "abstract"}, {"offsetInBeginSection": 1627, "offsetInEndSection": 1740, "text": "CONCLUSIONS: Interim analysis demonstrated no OS benefit for depatux-m in treating EGFR-amp newly diagnosed GBM. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35849035", "endSection": "abstract"}, {"offsetInBeginSection": 735, "offsetInEndSection": 1037, "text": "However, depatuxizumab mafodotin, an ADC targeting wild-type EGFR and EGFR variant III, did not provide a definitive overall survival benefit in patients with newly diagnosed or recurrent EGFR-amplified glioblastoma in phase II and III trials, despite objective radiological responses in some patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37085569", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "BACKGROUND: Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34050676", "endSection": "abstract"}, {"offsetInBeginSection": 1506, "offsetInEndSection": 1698, "text": "CONCLUSIONS: Despite profound intrinsic sensitivity to Depatux-M, limited drug delivery into brain tumor may have been a key contributor to lack of efficacy in recently failed clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34050676", "endSection": "abstract"}, {"offsetInBeginSection": 1612, "offsetInEndSection": 1799, "text": "CONCLUSIONS: Depatux-M had no impact on HRQoL and NDFS in patients with EGFR-amplified recurrent glioblastoma, except for more visual disorders, an expected side-effect of the study drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33601293", "endSection": "abstract"}, {"offsetInBeginSection": 1560, "offsetInEndSection": 1926, "text": "CONCLUSIONS: The study reported the first \"real world\" experience of Depatux-M plus temozolomide in recurrent glioblastoma patients. Encouraging clinical benefits were demonstrated, even though most patients were treated beyond second-line therapy. Overall, the results are close to those reported in the previous phase 2 trial. Toxicity was moderate and manageable.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34204877", "endSection": "abstract"}]}, {"body": "Can Nitrofurantoin cause Lung Injury?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37809109", "http://www.ncbi.nlm.nih.gov/pubmed/34407964", "http://www.ncbi.nlm.nih.gov/pubmed/33243181", "http://www.ncbi.nlm.nih.gov/pubmed/33088545"], "ideal_answer": "Yes, nitrofurantoin can cause lung injury. Although rare, acute lung injury resulting from nitrofurantoin can occur and is a life-threatening complication. Symptoms include respiratory distress, fevers, rash, eosinophilia, and new-onset atrial fibrillation. Treatment involves discontinuing the drug and possibly using glucocorticoids for persistent oxygen demand. Regular monitoring and early recognition are crucial to prevent irreversible fibrosis.", "exact_answer": "yes", "type": "yesno", "id": "65cfcf201930410b1300001b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Nitrofurantoin-Induced Lung Injury: A Reminder of an Overlooked Threat.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109", "endSection": "title"}, {"offsetInBeginSection": 112, "offsetInEndSection": 291, "text": "Although relatively rare, nitrofurantoin can cause a spectrum of lung injuries, from acute hypersensitivity reactions that might be fatal to chronic reactions involving fibrosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109", "endSection": "abstract"}, {"offsetInBeginSection": 1882, "offsetInEndSection": 2013, "text": "CONCLUSION: NF can cause marked or irreversible lung complications and there is currently a shortfall in awareness and monitoring. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34407964", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Reversible lung fibrosis in a 6-year-old girl after long term nitrofurantoin treatment.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33243181", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "BACKGROUND: Pulmonary side effects are well known, including lung fibrosis, in elderly patients treated with long-term nitrofurantoin to prevent urinary tract infections and secondary renal injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33243181", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "A rare case of nitrofurantoin-induced acute lung injury.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088545", "endSection": "title"}, {"offsetInBeginSection": 67, "offsetInEndSection": 189, "text": "Acute lung injury resulting from nitrofurantoin is a rare, life-threatening complication with women being at greater risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088545", "endSection": "abstract"}]}, {"body": "Which tick genus is the vector for Lyme disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37042198", "http://www.ncbi.nlm.nih.gov/pubmed/36958955", "http://www.ncbi.nlm.nih.gov/pubmed/36944114"], "ideal_answer": "The tick genus Ixodes is the vector for Lyme disease.", "exact_answer": [["Ixodes"]], "type": "factoid", "id": "660c0071fdcbea915f00002b", "snippets": [{"offsetInBeginSection": 316, "offsetInEndSection": 330, "text": "Ixodes ricinus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37042198", "endSection": "abstract"}, {"offsetInBeginSection": 132, "offsetInEndSection": 149, "text": "Ixodes scapularis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36958955", "endSection": "abstract"}, {"offsetInBeginSection": 53, "offsetInEndSection": 65, "text": "Ixodes ticks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36944114", "endSection": "abstract"}]}, {"body": "What disease was studied in the ANGEL-ASPECT trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36762852", "http://www.ncbi.nlm.nih.gov/pubmed/36137599", "http://www.ncbi.nlm.nih.gov/pubmed/37156088", "http://www.ncbi.nlm.nih.gov/pubmed/38010691"], "ideal_answer": "The ANGEL-ASPECT trial studied acute anterior circulation large vessel occlusion (LVO) in stroke patients.", "type": "summary", "id": "65d145651930410b13000042", "snippets": [{"offsetInBeginSection": 2150, "offsetInEndSection": 2514, "text": "CONCLUSIONS: In a trial conducted in China, patients with large cerebral infarctions had better outcomes with endovascular therapy administered within 24 hours than with medical management alone but had more intracranial hemorrhages. (Funded by Covidien Healthcare International Trading [Shanghai] and others; ANGEL-ASPECT ClinicalTrials.gov number, NCT04551664.).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36762852", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Endovascular therapy in acute anterior circulation large vessel occlusive patients with a large infarct core (ANGEL-ASPECT): protocol of a multicentre randomised trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36137599", "endSection": "title"}, {"offsetInBeginSection": 294, "offsetInEndSection": 801, "text": "DESIGN: ANGEL-ASPECT is a multicentre, prospective, randomised, open-label, blinded End-point trial to evaluate whether best medical management (BMM) combined with endovascular therapy improves neurological functional outcomes as compared with BMM alone in acute LVO patients with Alberta Stroke Program Early CT Score (ASPECTS) of 3-5 on non-contrast CT or infarct core volume range of 70-100\u2009mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI) up to 24 hours from symptom onset or last seen well.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36137599", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "OBJECTIVES: Recently published results of the ANGEL-ASPECT and SELECT2 trials suggest that stroke patients presenting with low Alberta Stroke Program Early Computed Tomography Score (ASPECTS) benefit from mechanical thrombectomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37156088", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Alberta Stroke Program Early Computed Tomography Score, Infarct Core Volume, and Endovascular Therapy Outcomes in Patients With Large Infarct: A Secondary Analysis of the ANGEL-ASPECT Trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38010691", "endSection": "title"}, {"offsetInBeginSection": 422, "offsetInEndSection": 703, "text": "This prespecified secondary analysis of subgroups of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core (ANGEL-ASPECT) RCT included patients from 46 stroke centers across China between October 2, 2020, and May 18, 2022.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38010691", "endSection": "abstract"}]}, {"body": "Is high blood pressure a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35016085"], "ideal_answer": "Yes, high blood pressure (hypertension) has been identified as a clinical biomarker of response to Bevacizumab in advanced colorectal cancer patients. Retrospective studies and a pooled analysis of prospective randomized trials have shown that patients who develop grade 2 or higher hypertension during treatment with Bevacizumab have longer progression-free survival (PFS) and overall survival (OS) compared to those who do not develop hypertension. This association remains significant even after correcting for time-dependency and considering pre-existing hypertension. Therefore, monitoring and managing blood pressure in patients receiving Bevacizumab may provide valuable prognostic information and guide treatment decisions.", "exact_answer": "yes", "type": "yesno", "id": "66099b20fdcbea915f000021", "snippets": [{"offsetInBeginSection": 2166, "offsetInEndSection": 2309, "text": "Bevacizumab-induced HTN during the first-line treatment of mCRC is an independent prognostic factor, also adopting a time-dependency correction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35016085", "endSection": "abstract"}, {"offsetInBeginSection": 1485, "offsetInEndSection": 1727, "text": "In TRIBE and TRIBE-2 study populations (N\u00a0=\u00a01175), patients experiencing\u00a0\u2265\u00a0G2 HTN during first-line bevacizumab administration showed longer PFS (median: 14.7 versus 10.3\u00a0months, p\u00a0<\u00a00.001) and OS (median: 31.7 versus 24.2\u00a0months, p\u00a0<\u00a00.001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35016085", "endSection": "abstract"}]}, {"body": "What is Microcoring used for", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34729291", "http://www.ncbi.nlm.nih.gov/pubmed/37218872"], "ideal_answer": "Microcoring technology (MCT) is used for scarless skin removal and treatment of enlarged pores. It involves the use of a modified, hollow hypodermic needle to safely remove skin without leaving a scar. MCT has shown promising results in terms of skin tightening, increase in skin thickness, and improvement of enlarged pores.", "exact_answer": [["Microcoring technology (MCT) is used for scarless skin removal and treatment of enlarged pores."]], "type": "factoid", "id": "65f37bb1c4010b4d7800000d", "snippets": [{"offsetInBeginSection": 935, "offsetInEndSection": 1188, "text": " MCT treatment of human skin is safe and well tolerated. Although further studies on efficacy are required to evaluate the full potential of MCT in skin rejuvenation, early findings such as skin tightening and increase in skin thickness are encouraging.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34729291", "endSection": "abstract"}]}, {"body": "What type of drug is administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33423644", "http://www.ncbi.nlm.nih.gov/pubmed/35943347", "http://www.ncbi.nlm.nih.gov/pubmed/33368142"], "ideal_answer": "Antenatal corticosteroids are administered to the mother for the prevention of lung immaturity when a preterm delivery is anticipated.", "exact_answer": [["Antenatal corticosteroids"]], "type": "factoid", "id": "660bb7f9fdcbea915f000029", "snippets": [{"offsetInBeginSection": 168, "offsetInEndSection": 388, "text": "The administration of antenatal corticosteroids, in cases of imminent preterm delivery, can enhance fetal lung maturation and reduce the incidence of respiratory distress syndrome, leading to improved neonatal outcomes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33423644", "endSection": "abstract"}, {"offsetInBeginSection": 615, "offsetInEndSection": 692, "text": "single course of antenatal corticosteroids from 24 up to 34 gestational weeks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33423644", "endSection": "abstract"}, {"offsetInBeginSection": 35, "offsetInEndSection": 133, "text": "use of antenatal corticosteroids to prevent respiratory distress syndrome (RDS) in preterm infants", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35943347", "endSection": "abstract"}, {"offsetInBeginSection": 225, "offsetInEndSection": 386, "text": "beneficial effect of antenatal corticosteroids on fetal lung maturation and widespread recommendations to use this treatment in women at risk of preterm delivery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33368142", "endSection": "abstract"}, {"offsetInBeginSection": 804, "offsetInEndSection": 904, "text": "course of corticosteroids to women prior to anticipated preterm birth (before 37 weeks of pregnancy)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33368142", "endSection": "abstract"}, {"offsetInBeginSection": 5025, "offsetInEndSection": 5146, "text": "use of a single course of antenatal corticosteroids to accelerate fetal lung maturation in women at risk of preterm birth", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33368142", "endSection": "abstract"}]}, {"body": "What is the mechanism by which the microbiota modulates the effectiveness of immunotherapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34485534"], "ideal_answer": "The microbiota can modulate the effectiveness of immunotherapy by influencing the host immune system and the tumor microenvironment. Certain bacteria can activate immunity and enhance the anti-tumor response, while others can mediate immunosuppression and help cancer cells evade the immune system. The composition of the gut microbiota can serve as biomarkers to predict the prognosis of immunotherapy and may be used to develop interventions that improve treatment outcomes.", "type": "summary", "id": "65f7794dc4010b4d78000037", "snippets": [{"offsetInBeginSection": 481, "offsetInEndSection": 740, "text": "The microbiota may affect tumor immunity by regulating the host immune system and tumor microenvironment. Some bacteria help fight tumors by activating immunity, while some bacteria mediate immunosuppression to help cancer cells escape from the immune system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34485534", "endSection": "abstract"}]}, {"body": "What disease is treated with Teplizumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37502867", "http://www.ncbi.nlm.nih.gov/pubmed/37256143", "http://www.ncbi.nlm.nih.gov/pubmed/37296593", "http://www.ncbi.nlm.nih.gov/pubmed/35533645", "http://www.ncbi.nlm.nih.gov/pubmed/36741943", "http://www.ncbi.nlm.nih.gov/pubmed/36896700", "http://www.ncbi.nlm.nih.gov/pubmed/36877454"], "ideal_answer": "Teplizumab is used for the treatment of type 1 diabetes (T1D).", "exact_answer": [["Teplizumab is used for the treatment of type 1 diabetes (T1D)."]], "type": "factoid", "id": "65cf6ae91930410b13000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Teplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37502867", "endSection": "abstract"}, {"offsetInBeginSection": 650, "offsetInEndSection": 802, "text": "An anti-CD3 antibody, teplizumab, was recently shown to delay clinical progression to T1D in high-risk individuals including adults and older children. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256143", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 781, "text": "Within the National Clinical Trial (NCT) database, a vast majority of over 3000 trials to treat T1D are devoted to insulin therapy. This review focuses on non-insulin pharmacological therapies. Many investigational new drugs fall under the category of immunomodulators, such as the recently FDA-approved CD-3 monoclonal antibody teplizumab. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37296593", "endSection": "abstract"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1307, "text": "Furthermore, regarding the timing of intervention, teplizumab was the first immunomodulatory agent to demonstrate a significant delay in disease progression in high-risk individuals before clinical onset.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533645", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 466, "text": "Context: Participants with stage 1 or 2 type 1 diabetes (T1D) qualify for prevention trials, but factors involved in screening for such trials are largely unknown.Objective: To identify factors associated with screening for T1D prevention trials.Methods: This study included TrialNet Pathway to Prevention participants who were eligible for a prevention trial: oral insulin (TN-07, TN-20), teplizumab (TN-10), abatacept (TN-18), and oral hydroxychloroquine (TN-22). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36741943", "endSection": "abstract"}, {"offsetInBeginSection": 496, "offsetInEndSection": 762, "text": "We focus on phase 2 clinical trials with promising results, thus avoiding the exhausted list of every new therapy for T1DM.EXPERT OPINION: Teplizumab has demonstrated potential as a preventative agent for individuals at risk prior to the onset of overt dysglycemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36896700", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 434, "text": "Teplizumab (teplizumab-mzwv; TZIELD\u2122) is a CD3-directed monoclonal antibody (humanized IgG1\u03ba) that is being developed by Provention Bio, Inc. for the treatment of type 1 diabetes (T1D). In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D, based on results of a clinical trial in high-risk relatives of individuals with T1D. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36877454", "endSection": "abstract"}]}, {"body": "List the causes of Restrictive cardiomyopathy (RCM)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28912185"], "ideal_answer": "The causes of Restrictive cardiomyopathy (RCM) include cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis. These three conditions are characterized by a nondilated left or right ventricle with diastolic dysfunction. Early recognition of these diseases is crucial for improving survival.", "exact_answer": [["Cardiac amyloidosis"], ["Cardiac sarcoidosis"], ["Cardiac hemochromatosis"]], "type": "list", "id": "65f1d9f8c4010b4d78000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 552, "text": "Restrictive cardiomyopathy (RCM) is characterized by nondilated left or right ventricle with diastolic dysfunction. The restrictive cardiomyopathies are a heterogenous group of myocardial diseases that vary according to pathogenesis, clinical presentation, diagnostic evaluation and criteria, treatment, and prognosis. In this review, an overview of RCMs will be presented followed by a detailed discussion on 3 major causes of RCM, for which tailored interventions are available: cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28912185", "endSection": "abstract"}]}, {"body": "Is Trifluridine/Tipiracil a preferential treatment over Regorafenib in elderly colorectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34406678", "http://www.ncbi.nlm.nih.gov/pubmed/28894015"], "ideal_answer": "Based on the available evidence, Trifluridine/Tipiracil (FTD/TPI) may be a preferential treatment over Regorafenib in elderly colorectal cancer patients. A retrospective cohort study showed that FTD/TPI had better tumor response and disease control rates compared to Regorafenib in patients with refractory metastatic colorectal cancer. Subgroup analysis also suggested that early use of FTD/TPI may have clinical benefits in second- or third-line therapy. However, further studies are needed to confirm these findings and identify predictive biomarkers to guide treatment selection.", "exact_answer": "no", "type": "yesno", "id": "65f7778fc4010b4d78000031", "snippets": [{"offsetInBeginSection": 1664, "offsetInEndSection": 1778, "text": "Patients treated with FTD/TPI had better tumor response and disease control than patients treated with regorafenib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34406678", "endSection": "abstract"}, {"offsetInBeginSection": 2180, "offsetInEndSection": 2460, "text": "Although no difference in overall survival was found between the two drugs in adjusted analysis using propensity score, regorafenib showed favorable survival in patients aged <65 years, whereas trifluridine/tipiracil was favored in patients aged \u226565 years in the subgroup analysis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28894015", "endSection": "abstract"}, {"offsetInBeginSection": 1194, "offsetInEndSection": 1372, "text": "Regorafenib showed favorable survival in patients aged <65 years (HR, 1.29; 95% CI, 0.98-1.69), whereas TFTD was favored in patients aged \u226565 years (HR, 0.78; 95% CI, 0.59-1.03).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28894015", "endSection": "abstract"}]}, {"body": "Is watch-and-wait policy after neoadjuvant therapy a cost-effective policy for locally advanced rectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31930400"], "ideal_answer": "Yes, the watch-and-wait (WW) policy after neoadjuvant therapy is a cost-effective policy for locally advanced rectal cancer patients. According to a decision-analytic model, the WW strategy offers comparable cancer-specific survival, superior quality-adjusted survival, and reduced costs compared to upfront total mesorectal excision (TME). In the study, WW was found to be dominant relative to both low anterior resection and abdominoperineal resection, with cost savings of $28,500 and $32,100 respectively. The incremental quality-adjusted life-years (QALY) were also higher for the WW strategy. However, upfront TME was preferred when the rate of surgical salvage was low. These findings suggest that the WW policy can be a cost-effective alternative for locally advanced rectal cancer patients who have achieved a clinical complete response to neoadjuvant therapy.", "exact_answer": "yes", "type": "yesno", "id": "65f778dbc4010b4d78000035", "snippets": [{"offsetInBeginSection": 1566, "offsetInEndSection": 1825, "text": "Using current multi-institutional recurrence estimates, we observed comparable cancer-specific survival, superior quality-adjusted survival, and decreased costs with WW compared with upfront TME. Upfront TME was preferred when surgical salvage rates were low.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31930400", "endSection": "abstract"}]}, {"body": "What is the appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37142372"], "ideal_answer": "The appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is the combination of tucatinib and trastuzumab. This treatment has shown clinically meaningful anti-tumor activity and favorable tolerability, making it the first FDA-approved anti-HER2 regimen for metastatic colorectal cancer. It is an important new treatment option for patients with chemotherapy-refractory HER2-positive metastatic colorectal cancer.", "exact_answer": [["The appropriate treatment in HER2Neu amplificated refractory advanced colorectal cancer patients is tucatinib plus trastuzumab."]], "type": "factoid", "id": "65f77a71c4010b4d7800003b", "snippets": [{"offsetInBeginSection": 3128, "offsetInEndSection": 3463, "text": "Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37142372", "endSection": "abstract"}]}, {"body": "What is the results of diphthamide deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33704902", "http://www.ncbi.nlm.nih.gov/pubmed/35781884", "http://www.ncbi.nlm.nih.gov/pubmed/32576952"], "ideal_answer": "Diphthamide deficiency results in developmental delay, short stature, sparse hair, and facial dysmorphism. It can also lead to unusual skull shape, dysplastic toenails, dental abnormalities, and congenital heart disease. In some cases, growth hormone deficiency may be present. Diphthamide deficiency affects the accuracy of ribosomal protein biosynthesis and reduces the translation elongation rate in hepatocytes. It can inhibit pericentral hepatocyte-derived tumors and promote periportal progenitor-associated liver tumors.", "type": "summary", "id": "660a912dfdcbea915f000028", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 293, "text": "Variants of the diphthamide biosynthesis I (DPH1, OMIM*603527) are associated with developmental delay, short stature, and sparse hair syndrome (DEDSSH/DPH1 syndrome) (OMIM# 616901). Another name is Loucks-Innes syndrome. DPH1 syndrome is an ultrarare and severe neurodevelopmental disorder. L", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33704902", "endSection": "abstract"}, {"offsetInBeginSection": 2109, "offsetInEndSection": 2389, "text": "These findings indicate that diphthamide deficiency differentially regulates hepatocellular carcinogenesis, which inhibits pericentral hepatocyte-derived tumors and promotes periportal progenitor-associated liver tumors. \u00a9 2022 The Pathological Society of Great Britain and Irelan", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35781884", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Diphthamide-deficiency syndrome: a novel human developmental disorder and ribosomopathy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32576952", "endSection": "title"}, {"offsetInBeginSection": 430, "offsetInEndSection": 628, "text": "he human DPH1 syndrome is an autosomal recessive disorder associated with developmental delay, abnormal head circumference (microcephaly or macrocephaly), short stature, and congenital heart disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32576952", "endSection": "abstract"}]}, {"body": "Is Omaveloxolone effective for Friedreich Ataxia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33068037", "http://www.ncbi.nlm.nih.gov/pubmed/33430645", "http://www.ncbi.nlm.nih.gov/pubmed/38020600", "http://www.ncbi.nlm.nih.gov/pubmed/37691319", "http://www.ncbi.nlm.nih.gov/pubmed/37155124", "http://www.ncbi.nlm.nih.gov/pubmed/37219716"], "ideal_answer": "Yes, omaveloxolone has shown effectiveness in the treatment of Friedreich's ataxia. In a phase 2 trial, omaveloxolone significantly improved neurological function compared to placebo, as measured by the modified Friedreich's Ataxia Rating Scale (mFARS) score. The trial demonstrated that omaveloxolone improved mitochondrial function, restored redox balance, and reduced inflammation in patients with Friedreich's ataxia. This indicates that omaveloxolone has the potential to be a therapeutic agent for Friedreich's ataxia.", "exact_answer": "yes", "type": "yesno", "id": "65d12c451930410b13000032", "snippets": [{"offsetInBeginSection": 1587, "offsetInEndSection": 1796, "text": "INTERPRETATION: In the MOXIe trial, omaveloxolone significantly improved neurological function compared to placebo and was generally safe and well tolerated. It represents a potential therapeutic agent in FA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33068037", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Omaveloxolone: potential new agent for Friedreich ataxia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33430645", "endSection": "title"}, {"offsetInBeginSection": 517, "offsetInEndSection": 786, "text": "In this work, we review the evidence for use of omaveloxolone in FRDA from recent clinical trials. Though not at present approved for any indication, the present data suggest that this agent acting though increases in Nrf2 activity may provide a novel therapy for FRDA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33430645", "endSection": "abstract"}, {"offsetInBeginSection": 366, "offsetInEndSection": 506, "text": "Omaveloxolone has been recently approved as the first pharmacological treatment for FRDA in adults and adolescents aged 16\u2009years and older. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38020600", "endSection": "abstract"}, {"offsetInBeginSection": 1450, "offsetInEndSection": 1684, "text": "INTERPRETATION: These results suggest a meaningful slowing of Friedreich ataxia progression with omaveloxolone, and consequently detail how propensity-matched analysis may contribute to understanding of effects of therapeutic agents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37691319", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Omaveloxolone (SKYCLARYS\u2122) is an orally active, small molecule semi-synthetic triterpenoid drug that increases antioxidant activity, which is being developed by Reata Pharmaceuticals, Inc. for the treatment of Friedreich's ataxia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37155124", "endSection": "abstract"}, {"offsetInBeginSection": 588, "offsetInEndSection": 685, "text": "Omaveloxolone was approved in February 2023 in the USA for the treatment of Friedreich's ataxia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37155124", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37219716", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 310, "text": "The exciting news about the US FDA approval of omaveloxolone as the first-ever drug to be approved for an inherited ataxia is welcome news for patients and families that deal with this devastating disease as well as for health care providers and investigators with an interest in this and other rare diseases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37219716", "endSection": "abstract"}]}, {"body": "TAK-994 is developed for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37494485", "http://www.ncbi.nlm.nih.gov/pubmed/37001988"], "ideal_answer": "TAK-994 is developed for the treatment of narcolepsy type 1.", "exact_answer": [["TAK-994 is developed for narcolepsy type 1."]], "type": "factoid", "id": "65cfd3961930410b1300001f", "snippets": [{"offsetInBeginSection": 93, "offsetInEndSection": 255, "text": "METHODS: We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37494485", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37001988", "endSection": "title"}, {"offsetInBeginSection": 2127, "offsetInEndSection": 2277, "text": "These findings indicate that TAK-994 is an orally available brain-penetrant OX2R-selective agonist with potential to improve narcolepsy-like symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37001988", "endSection": "abstract"}]}, {"body": "What is the target of Divarasib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37611121", "http://www.ncbi.nlm.nih.gov/pubmed/37774359", "http://www.ncbi.nlm.nih.gov/pubmed/38052910"], "ideal_answer": "The target of Divarasib is the KRAS G12C mutation, which is prevalent in certain solid tumors such as non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors.", "exact_answer": [["The target of Divarasib is the KRAS G12C mutation."]], "type": "factoid", "id": "65cfaf7e1930410b13000016", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "BACKGROUND: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121", "endSection": "abstract"}, {"offsetInBeginSection": 1706, "offsetInEndSection": 1854, "text": "CONCLUSIONS: Treatment with divarasib resulted in durable clinical responses across KRAS G12C-positive tumors, with mostly low-grade adverse events.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37611121", "endSection": "abstract"}, {"offsetInBeginSection": 437, "offsetInEndSection": 700, "text": "Here, we describe the identification and characterization of GDC-1971 (formerly RLY-1971), a SHP2 inhibitor currently in clinical trials in combination with KRAS G12C inhibitor divarasib (GDC-6036) for the treatment of solid tumors driven by a KRAS G12C mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37774359", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38052910", "endSection": "title"}, {"offsetInBeginSection": 105, "offsetInEndSection": 220, "text": "Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400\u2009mg. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38052910", "endSection": "abstract"}, {"offsetInBeginSection": 1404, "offsetInEndSection": 1577, "text": "The manageable safety profile and encouraging antitumor activity of divarasib plus cetuximab support the further investigation of this combination in KRAS G12C-positive CRC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38052910", "endSection": "abstract"}]}, {"body": "What is the most effective drug for oxaliplatin-induced neuropathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32471028", "http://www.ncbi.nlm.nih.gov/pubmed/34880120"], "ideal_answer": "Currently, there is limited evidence for the efficacy of duloxetine in the treatment of oxaliplatin-induced neuropathy. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN). However, it is only effective in little more than half of patients, and our ability to predict patient response remains incompletely understood. Further research is needed to identify more effective treatments for oxaliplatin-induced neuropathy.", "exact_answer": [["Duloxetine"]], "type": "factoid", "id": "66099926fdcbea915f000016", "snippets": [{"offsetInBeginSection": 664, "offsetInEndSection": 760, "text": "only limited evidence for the efficacy of duloxetine in the treatment setting has been provided.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32471028", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is the best-established treatment for painful chemotherapy-induced peripheral neuropathy (CIPN)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34880120", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of Zilebesiran?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37467498", "http://www.ncbi.nlm.nih.gov/pubmed/37706295", "http://www.ncbi.nlm.nih.gov/pubmed/37897397"], "ideal_answer": "Zilebesiran is an investigational RNA interference therapeutic agent that inhibits hepatic angiotensinogen synthesis. By targeting and reducing the production of angiotensinogen, Zilebesiran disrupts the renin-angiotensin system, leading to a decrease in blood pressure.", "type": "summary", "id": "65cfd7981930410b13000022", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467498", "endSection": "title"}, {"offsetInBeginSection": 130, "offsetInEndSection": 276, "text": "Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467498", "endSection": "abstract"}, {"offsetInBeginSection": 360, "offsetInEndSection": 969, "text": "Dysregulation of the renin-angiotensin system increases BP through its primary effector, Ang II (angiotensin II), which results in tissue remodeling and end-organ damage. Silencing liver angiotensinogen (the sole source of Ang II) has been achieved using novel RNA therapeutics, including the antisense oligonucleotide, IONIS-AGT (angiotensinogen)-LRX, and the small-interfering RNA, zilebesiran. Conjugation to N-acetylgalactosamine enables targeted delivery to hepatocytes, where endosomal storage, slow leakage, and small-interfering RNA recycling (for zilebesiran) result in knockdown over several months.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37706295", "endSection": "abstract"}, {"offsetInBeginSection": 735, "offsetInEndSection": 921, "text": "We present an analysis of the published phase I trials using zilebesiran, a siRNA targeting hepatic angiotensinogen, which reduces blood pressure (BP) by up to 20\u2009mmHg, lasting 24\u2009weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37897397", "endSection": "abstract"}]}, {"body": "Is Tako-Tsubo syndrome is an irreversible form of an acute stress-related cardiomyopathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/38090463", "http://www.ncbi.nlm.nih.gov/pubmed/25788945", "http://www.ncbi.nlm.nih.gov/pubmed/31752657"], "ideal_answer": "No, Tako-Tsubo syndrome is a reversible form of acute stress-related cardiomyopathy. It is characterized by acute left ventricular segmental dysfunction, resembling acute myocardial infarction. The syndrome often follows a psychophysical stressful event and is characterized by echocardiographic evidence of akinesia of the left ventricular mid-apical segments. With supportive and symptomatic medication, the left ventricle function improves over several days, leading to full recovery within three to four weeks.", "exact_answer": "no", "type": "yesno", "id": "6609827afdcbea915f000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Takotsubo cardiomyopathy (TC) is a recognized clinical syndrome characterized by reversible cardiomyopathy with a distinctive left ventricular apical ballooning appearance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090463", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Tako-Tsubo cardiomyopathy (TTC) is a reversible cardiomyopathy characterized by acute left ventricular segmental dysfunction, whose clinical presentation resembles that of acute myocardial infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25788945", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 178, "text": "Takotsubo Cardiomyopathy (TTC) is an uncommon cause of acute reversible ventricular systolic dysfunction in the absence of obstructive Coronary Artery Disease (CAD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752657", "endSection": "abstract"}]}, {"body": "What is the use of fezolinetant?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36734148", "http://www.ncbi.nlm.nih.gov/pubmed/36470539", "http://www.ncbi.nlm.nih.gov/pubmed/37343519", "http://www.ncbi.nlm.nih.gov/pubmed/37462862"], "ideal_answer": "Fezolinetant is used for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes associated with menopause.", "type": "summary", "id": "65d136f41930410b1300003d", "snippets": [{"offsetInBeginSection": 111, "offsetInEndSection": 239, "text": "OBJECTIVE: We aimed to assess efficacy/safety of fezolinetant for treatment of moderate to severe VMS associated with menopause.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36734148", "endSection": "abstract"}, {"offsetInBeginSection": 1512, "offsetInEndSection": 1654, "text": "CONCLUSION: Daily fezolinetant 30 and 45 mg were efficacious and well tolerated for treating moderate to severe VMS associated with menopause.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36734148", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Fezolinetant is a neurokinin 3 receptor antagonist under investigation for treatment of menopausal symptoms. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37343519", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 238, "text": "Fezolinetant (VEOZAH\u2122) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862", "endSection": "abstract"}]}]}
